<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82037</article-id><article-id pub-id-type="doi">10.7554/eLife.82037</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast <italic>S. boulardii</italic> CNCM I-745 reduces bone loss in osteoporosis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-288262"><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-182749"><name><surname>Halper</surname><given-names>Julia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3967-6633</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170206"><name><surname>Ibáñez</surname><given-names>Lidia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2217-8817</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288272"><name><surname>Claire</surname><given-names>Lozano</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288263"><name><surname>Rouleau</surname><given-names>Matthieu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0075-9880</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288264"><name><surname>Boutin</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-303712"><name><surname>Mahler</surname><given-names>Adrien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288265"><name><surname>Pontier-Bres</surname><given-names>Rodolphe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4139-5913</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288266"><name><surname>Ciucci</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5828-0207</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="pa1">§</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288267"><name><surname>Topi</surname><given-names>Majlinda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170210"><name><surname>Hue</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288268"><name><surname>Amiaud</surname><given-names>Jerome</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288269"><name><surname>Iborra</surname><given-names>Salvador</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20139"><name><surname>Sancho</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-226672"><name><surname>Heymann</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-170211"><name><surname>Garchon</surname><given-names>Henri-Jean</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288270"><name><surname>Czerucka</surname><given-names>Dorota</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-37844"><name><surname>Apparailly</surname><given-names>Florence</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30308"><name><surname>Duroux-Richard</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-288271"><name><surname>Wakkach</surname><given-names>Abdelilah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-286942"><name><surname>Blin-Wakkach</surname><given-names>Claudine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2621-3907</contrib-id><email>claudine.blin@univ-cotedazur.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/019tgvf94</institution-id><institution>Université Côte d’Azur, CNRS, LP2M</institution></institution-wrap><addr-line><named-content content-type="city">Nice</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02n399288</institution-id><institution>LIA ROPSE, Laboratoire International Associé Université Côte d’Azur - Centre Scientifique de Monaco</institution></institution-wrap><addr-line><named-content content-type="city">Nice and Monaco</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tnh0829</institution-id><institution>Department of Pharmacy, Cardenal Herrera-CEU University</institution></institution-wrap><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b8mh310</institution-id><institution>IRMB, Université Montpellier</institution></institution-wrap><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04kptf457</institution-id><institution>Centre Scientifique</institution></institution-wrap><addr-line><named-content content-type="city">de Monaco</named-content></addr-line><country>Monaco</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation</institution></institution-wrap><addr-line><named-content content-type="city">Montigny-Le-Bretonneux</named-content></addr-line><country>France</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>Inserm, Universite de Nantes</institution></institution-wrap><addr-line><named-content content-type="city">Nantes</named-content></addr-line><country>France</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02p0gd045</institution-id><institution>Department of Immunology, Ophthalmology and ENT. School of Medicine, Universidad Complutense de Madrid</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qs1a797</institution-id><institution>Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01m6as704</institution-id><institution>Université de Nantes, Institut de Cancérologie de l’Ouest</institution></institution-wrap><addr-line><named-content content-type="city">Saint Herblain</named-content></addr-line><country>France</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03j6rvb05</institution-id><institution>Genetics Division, Ambroise Paré Hospital, AP-HP</institution></institution-wrap><addr-line><named-content content-type="city">Boulogne-Billancourt</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Li</surname><given-names>Yi-Ping</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vmvtb21</institution-id><institution>Tulane University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>§</label><p>David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>27</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e82037</elocation-id><history><date date-type="received" iso-8601-date="2022-07-20"><day>20</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-12"><day>12</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-08-03"><day>03</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.01.502322"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-82037-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-82037-figures-v1.pdf"/><abstract><p>Bone destruction is a hallmark of chronic inflammation, and bone-resorbing osteoclasts arising under such a condition differ from steady-state ones. However, osteoclast diversity remains poorly explored. Here, we combined transcriptomic profiling, differentiation assays and in vivo analysis in mouse to decipher specific traits for inflammatory and steady-state osteoclasts. We identified and validated the pattern-recognition receptors (PRR) Tlr2, Dectin-1, and Mincle, all involved in yeast recognition as major regulators of inflammatory osteoclasts. We showed that administration of the yeast probiotic <italic>Saccharomyces boulardii</italic> CNCM I-745 (<italic>Sb</italic>) in vivo reduced bone loss in ovariectomized but not sham mice by reducing inflammatory osteoclastogenesis. This beneficial impact of <italic>Sb</italic> is mediated by the regulation of the inflammatory environment required for the generation of inflammatory osteoclasts. We also showed that <italic>Sb</italic> derivatives as well as agonists of Tlr2, Dectin-1, and Mincle specifically inhibited directly the differentiation of inflammatory but not steady-state osteoclasts in vitro. These findings demonstrate a preferential use of the PRR-associated costimulatory differentiation pathway by inflammatory osteoclasts, thus enabling their specific inhibition, which opens new therapeutic perspectives for inflammatory bone loss.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>osteoclast</kwd><kwd>osteoporosis</kwd><kwd>osteoimmunology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-16-CE14-0030</award-id><principal-award-recipient><name><surname>Garchon</surname><given-names>Henri-Jean</given-names></name><name><surname>Garchon</surname><given-names>Henri-Jean</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002915</institution-id><institution>Fondation pour la Recherche Médicale</institution></institution-wrap></funding-source><award-id>ECO20160736019</award-id><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-15-IDEX-01</award-id><principal-award-recipient><name><surname>Madel</surname><given-names>Maria-Bernadette</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Transcriptomic comparison of inflammatory and steady-state osteoclasts reveals differences in their ability to sense their environment, which makes it possible to selectively inhibit inflammatory osteoclastogenesis and reduce bone loss in osteoporosis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Osteoclasts (OCLs) are multinucleated phagocytes derived from monocytic progenitors and specialized in bone resorption (<xref ref-type="bibr" rid="bib35">Madel et al., 2019</xref>). Similar to other cells of monocytic origin, they are also innate immunocompetent cells and heterogeneous in their phenotype, function, and origin (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Jacome-Galarza et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Madel et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Yahara et al., 2020</xref>). OCLs derived from steady-state bone marrow (BM) cells or from BM CD11b<sup>+</sup> monocytic cells (MN-OCLs) promote tolerance by inducing CD4<sup>+</sup> and CD8<sup>+</sup> regulatory T cells (tolerogenic OCLs [t-OCLs]) (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Kiesel et al., 2009</xref>). In contrast, in the context of bone destruction linked to inflammatory bowel disease (IBD) or when derived from dendritic cells (DC-OCLs), OCLs induce Tnf-α-producing CD4<sup>+</sup> T cells (inflammatory OCLs [i-OCLs]) (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>). OCLs associated with inflammation can be identified by expression of Cx3cr1 (fractalkine receptor) and the proportion of Cx3cr1<sup>+</sup> OCLs increases in osteoporosis, IBD, and after Rank-L treatment (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>). However, Cx3cr1 is only expressed in approximately 20% of i-OCLs (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>), which highlights their heterogeneity while limiting the possibility to analyze them in the context of pathological bone loss and urges the identification of novel markers.</p><p>Current anti-resorptive therapies aim to globally inhibit OCLs, without considering their recently established diversity. In the long term, they result in poor bone remodeling which may increase the risk of atypical fractures (<xref ref-type="bibr" rid="bib49">Reyes et al., 2016</xref>). Therefore, an in-depth characterization of OCLs associated with healthy versus inflammatory bone resorption would allow the identification of distinct characteristics that could help to specifically target i-OCL.</p><p>i-OCLs arise under the control of persistent high levels of Rank-L, IL-17, and TNFα mainly produced by CD4<sup>+</sup> T cells that play a major role in pathological osteoclastogenesis observed in osteoporosis and IBD (<xref ref-type="bibr" rid="bib4">Cenci et al., 2000</xref>; <xref ref-type="bibr" rid="bib5">Ciucci et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Li et al., 2011</xref>). Interestingly, the emergence of such osteoclastogenic CD4<sup>+</sup> T cells is associated with gut dysbiosis and increased intestinal permeability (<xref ref-type="bibr" rid="bib24">Jones et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2016</xref>). In line with this, bacterial probiotics such as <italic>Lactobacillus</italic> and <italic>Bifidobacteria</italic> have been shown to effectively reduce osteoporotic bone loss (<xref ref-type="bibr" rid="bib30">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib3">Britton et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Ohlsson et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Ibáñez et al., 2019b</xref>), but their specific effect on i-OCLs remains unknown.</p><p>Here, using a comparative RNAseq approach performed on sorted pure mature MN-OCLs and DC-OCLs as models of t-OCLs and i-OCLs, respectively, as already established (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>), we showed that the two OCL populations are distinctly equipped to respond to different signals that can modulate their differentiation. In particular, the pattern recognition receptors (PRRs) Dectin-1, Tlr2, and Mincle involved in the response to fungi (<xref ref-type="bibr" rid="bib31">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Sancho and Reis e Sousa, 2012</xref>) are overexpressed in i-OCLs. Administration of the probiotic yeast <italic>Saccharomyces boulardii</italic> CNCM I-745 (<italic>Sb</italic>), which is used in the treatment of gastrointestinal disorders for its anti-inflammatory properties and its capacity to restore the gut microbiota (<xref ref-type="bibr" rid="bib6">Czerucka and Rampal, 2019</xref>; <xref ref-type="bibr" rid="bib57">Terciolo et al., 2019</xref>), significantly reduces bone loss and inflammatory parameters in vivo in ovariectomized (OVX) mice. In vitro, Sb derivates as well as low doses of agonists of the PRRs overexpressed in i-OCLs specifically inhibit the differentiation of these cells without affecting t-OCLs. These data open perspectives on targeting specific OCL populations and provide evidence for the protective effect of a probiotic yeast on inflammatory bone resorption. Our study unveils very new insights into the regulation and modulation of i-OCLs and enables a better understanding of the molecular mechanisms involved in inflammation-induced bone erosions.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Transcriptomic profiling reveals upregulation of innate immune receptors in i-OCLs</title><p>To better understand the differences between t-OCLs and i-OCLs, we performed a comparative RNA-sequencing (RNAseq) analysis between sorted mature (≥three nuclei) MN-OCLs (originating from BM CD11b<sup>+</sup> monocytic cells) and DC-OCLs (differentiated from BM-derived DCs) representing t-OCLs and i-OCLs, respectively, as already demonstrated (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a–b</xref>). A total of 906 genes (log<sub>2</sub>FC (Fold Change) ≥1; p&lt;0.05) were significantly differentially expressed between the two OCL subsets (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), including <italic>Cx3cr1</italic> previously identified as a marker of i-OCLs (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>). The most differentially expressed genes were related to innate immunity and immune defense responses (<xref ref-type="fig" rid="fig1">Figure 1b–d</xref>), confirming our previous observation that i-OCLs and t-OCLs differ in their immune capacity (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Comparative transcriptomic analysis of inflammatory osteoclasts (i-OCLs) versus tolerogenic OCLs (t-OCLs) reveals two distinct populations of OCLs and differences in their differentiation pathway.</title><p>(<bold>a</bold>) Volcano plot analysis of differentially expressed (DE) genes (p&lt;0.05; FC ≥2) between sorted mature i-OCLs (dendritic cells [DC]-derived OCLs) and t-OCLs (monocytic cells [MN]-derived OCLs) differentiated and sorted (≥ three nuclei) as presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Analysis was performed on n=5 biological replicates for each group. (<bold>b</bold>) Heatmap visualization of the z-scored expression of the top 70 genes (p&lt;0.05; FC ≥2) that are significantly DE between the two OCL subsets. (<bold>c</bold>) Gene ontology analysis of biological processes associated with DE genes. (<bold>d</bold>) EnrichR annotation (Kegg) for the 906 DE genes between MN-OCLs and DC-OCLs. (<bold>e</bold>) Transcriptomic analysis of selected genes (from Kegg mmu04380, osteoclast differentiation) involved in bone resorption (<italic>Acp5, Car2, Clcn7, Ctsk, Mmp9, Ostm1, Tcirg1</italic>), the Rank differentiation pathway (<italic>Chuk, Ikbkb, Ikbkg, Map2k1, Map2k7, Map3k7, Mapk8, Mapk9, Nfatc1, Nfkb1, Nfkb2, Tab1, Tab2, Tnfrsf11a, Traf2, Traf6</italic>), and the co-stimulatory differentiation pathway (<italic>Blnk, Fcgr1, Fcgr2b, Fcgr3, Fcgr4, Lilrb4a, Oscar, Plcg2, Sirpb1b, Sirpb1c, Syk, Trem2, Tyrobp</italic>) in i-OCLs and t-OCLs on n=5 biological replicates per group. (<bold>f</bold>) EnrichR annotation (Kegg) for the genes involved in the OCL co-stimulatory differentiation pathway (from <bold>d</bold>). (<bold>g</bold>) Volcano plot visualization of the comparative miRNome analysis of i-OCLs and t-OCLs performed on n=5 biological replicates for each group. (<bold>h</bold>) Quantitative real-time PCR analysis (mean ± standard deviation (SD)) on t-OCLs and i-OCLs (n=10 biological replicates per group). miRNA expression was normalized to the <italic>sno202</italic> expression using the 2<sup>−(ΔCt)</sup> method. (<bold>i</bold>) EnrichR annotation (Kegg) for the target genes (from <xref ref-type="table" rid="table2">Table 2</xref>) of the DE miRNAs. (<bold>j</bold>) Heatmap visualization of the RNAseq data for selected genes involved in the C-type lectin receptor and TLR (Toll Like Receptor) signaling pathway (from Kegg) in i-OCLs and t-OCLs. (<bold>k</bold>) FACS (Flow Cytometry Cell Sorting) histograms and quantification (mean ± SD) of mature i-OCLs and t-OCLs for the expression of Dectin-1 and 2, Tlr2, and Mincle. Mature OCLs were gated as shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>. (<bold>l</bold>) FACS analysis on BM-derived CD11c<sup>+</sup> DCs, and CD11b<sup>+</sup> BM cells (used as OCL progenitors) and quantification (mean ± SD) of positive cells for the expression of Dectin-1 and 2, Tlr2, and Mincle each marker. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cell preparation and gating strategies.</title><p>(<bold>a</bold>) Schematic representation of the experimental procedure for the generation of tolerogenic OCLs (t-OCLs) from bone marrow (BM) CD11b<sup>+</sup> monocytic cells (MNs) and i-OCLs from BM-derived CD11c<sup>+</sup> dendritic cells (BM-DCs), as previously described (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Madel et al., 2018</xref>). (<bold>b</bold>) Gating strategy for purification by cell sorting or for FACS analysis of mature osteoclasts (with three and more nuclei), after staining of DNA with H33342 and doublet exclusion according to the protocol we previously established (<xref ref-type="bibr" rid="bib34">Madel et al., 2018</xref>). This strategy was used for gating on multinucleated mature osteoclasts throughout the different analyses.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Volcano plot representation showed that the expression of genes involved in OCL resorbing activity as well as in the Rank-Rank-L differentiation pathway was not significantly different in the two OCL populations, except for <italic>Nfatc1</italic>. However, major differences were found in genes associated with the Ig-like receptor-dependent costimulatory OCL differentiation pathway (<xref ref-type="bibr" rid="bib26">Koga et al., 2004</xref>; <xref ref-type="bibr" rid="bib39">Merck et al., 2004</xref>; <xref ref-type="fig" rid="fig1">Figure 1e</xref>). Interestingly, annotation of these genes (EnrichR/Kegg analysis) highlighted that they are also linked to pathways related to immune responses and PRRs, notably the C-type lectin receptors (CLRs) (<xref ref-type="fig" rid="fig1">Figure 1f</xref>).</p><p>These results were confirmed by a global miRNA profiling on the same sorted mature OCL samples (≥three nuclei). Volcano plot visualization confirmed that the two OCL subsets differ also in their miRNA expression pattern (<xref ref-type="fig" rid="fig1">Figure 1g</xref>). Differentially expressed miRNAs (FC ≥2, p&lt;0.05, quantitative PCR [qPCR] cycle threshold [CT] values &lt;32) (<xref ref-type="table" rid="table1">Table 1</xref>) were further validated by quantitative real-time PCR (RT-qPCR) confirming that <italic>Mir151</italic>, <italic>Mir342</italic>, <italic>Mir146b,</italic> and <italic>Mir155</italic> were significantly upregulated in i-OCLs, and that <italic>Mir185</italic>, <italic>Mir674</italic>, <italic>Mir26b,</italic> and <italic>Mir29a</italic> were upregulated in t-OCLs (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). Using the miRWalk software that provides information on miRNA-target interactions (<xref ref-type="bibr" rid="bib10">Dweep and Gretz, 2015</xref>), we carried out an integrative analysis of these miRNAs and genes that were significantly differentially expressed between both OCL subsets to find possible relationships (<xref ref-type="table" rid="table2">Table 2</xref>). In agreement with the RNAseq analysis, computational analysis of these related genes (EnrichR/ Kegg analysis) also revealed an association with the OCL differentiation pathway as well as the C-lectin-like receptor pathway (<xref ref-type="fig" rid="fig1">Figure 1i</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>List of the miRNAs differentially expressed between t-OCLs and i-OCLs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Official symbol</th><th align="left" valign="bottom">Official name</th><th align="left" valign="bottom">CT value</th><th align="left" valign="bottom">Log 2 (FC)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Mir151</italic></td><td align="left" valign="bottom"><italic>mmu-miR-151–3</italic> p</td><td align="char" char="." valign="bottom">28.3</td><td align="char" char="." valign="bottom">–5.06</td><td align="char" char="." valign="bottom">0.04</td></tr><tr><td align="left" valign="bottom"><italic>Mir342</italic></td><td align="left" valign="bottom"><italic>mmu-miR-342–3</italic> p</td><td align="char" char="." valign="bottom">23.1</td><td align="char" char="." valign="bottom">–2.40</td><td align="char" char="." valign="bottom">0.018</td></tr><tr><td align="left" valign="bottom"><italic>Mir351</italic></td><td align="left" valign="bottom"><italic>rno-miR-351</italic></td><td align="char" char="." valign="bottom">29.1</td><td align="char" char="." valign="bottom">–1.94</td><td align="char" char="." valign="bottom">0.019</td></tr><tr><td align="left" valign="bottom"><italic>Mir125a</italic></td><td align="left" valign="bottom"><italic>mmu-miR-125a-3p</italic></td><td align="char" char="." valign="bottom">30.2</td><td align="char" char="." valign="bottom">–1.84</td><td align="char" char="." valign="bottom">0.041</td></tr><tr><td align="left" valign="bottom"><italic>Mir146b</italic></td><td align="left" valign="bottom"><italic>mmu-miR-146b</italic></td><td align="char" char="." valign="bottom">21.3</td><td align="char" char="." valign="bottom">–1.64</td><td align="char" char="." valign="bottom">0.001</td></tr><tr><td align="left" valign="bottom"><italic>Mir155</italic></td><td align="left" valign="bottom"><italic>mmu-miR-155</italic></td><td align="char" char="." valign="bottom">26.5</td><td align="char" char="." valign="bottom">–1.56</td><td align="char" char="." valign="bottom">0.011</td></tr><tr><td align="left" valign="bottom"><italic>Mir30e</italic></td><td align="left" valign="bottom"><italic>mmu-miR-30e</italic></td><td align="char" char="." valign="bottom">21.4</td><td align="char" char="." valign="bottom">0.59</td><td align="char" char="." valign="bottom">0.03</td></tr><tr><td align="left" valign="bottom"><italic>Mir106a</italic></td><td align="left" valign="bottom"><italic>mmu-miR-106a</italic></td><td align="char" char="." valign="bottom">17.8</td><td align="char" char="." valign="bottom">0.70</td><td align="char" char="." valign="bottom">0.011</td></tr><tr><td align="left" valign="bottom"><italic>Mir26b</italic></td><td align="left" valign="bottom"><italic>mmu-miR-26b</italic></td><td align="char" char="." valign="bottom">20.9</td><td align="char" char="." valign="bottom">0.70</td><td align="char" char="." valign="bottom">0.024</td></tr><tr><td align="left" valign="bottom"><italic>Mir17</italic></td><td align="left" valign="bottom"><italic>mmu-miR-17</italic></td><td align="char" char="." valign="bottom">17.0</td><td align="char" char="." valign="bottom">0.82</td><td align="char" char="." valign="bottom">0.005</td></tr><tr><td align="left" valign="bottom"><italic>Snord65</italic></td><td align="left" valign="bottom"><italic>snoRNA135</italic></td><td align="char" char="." valign="bottom">18.4</td><td align="char" char="." valign="bottom">0.90</td><td align="char" char="." valign="bottom">0.029</td></tr><tr><td align="left" valign="bottom"><italic>Mir29a</italic></td><td align="left" valign="bottom"><italic>mmu-miR-29a</italic></td><td align="char" char="." valign="bottom">19.1</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">0.012</td></tr><tr><td align="left" valign="bottom"><italic>Mir674</italic></td><td align="left" valign="bottom"><italic>mmu-miR-674</italic></td><td align="char" char="." valign="bottom">20.6</td><td align="char" char="." valign="bottom">1.06</td><td align="char" char="." valign="bottom">0.045</td></tr><tr><td align="left" valign="bottom"><italic>Mir185</italic></td><td align="left" valign="bottom"><italic>mmu-miR-185</italic></td><td align="char" char="." valign="bottom">23.8</td><td align="char" char="." valign="bottom">1.20</td><td align="char" char="." valign="bottom">0.036</td></tr><tr><td align="left" valign="bottom"><italic>Mir18a</italic></td><td align="left" valign="bottom"><italic>mmu-miR-18a</italic></td><td align="char" char="." valign="bottom">22.7</td><td align="char" char="." valign="bottom">1.71</td><td align="char" char="." valign="bottom">0.035</td></tr><tr><td align="left" valign="bottom"><italic>Mir148a</italic></td><td align="left" valign="bottom"><italic>mmu-miR-148a</italic></td><td align="char" char="." valign="bottom">23.7</td><td align="char" char="." valign="bottom">1.82</td><td align="char" char="." valign="bottom">0.039</td></tr><tr><td align="left" valign="bottom"><italic>Mir32</italic></td><td align="left" valign="bottom"><italic>mmu-miR-32</italic></td><td align="char" char="." valign="bottom">28.6</td><td align="char" char="." valign="bottom">2.45</td><td align="char" char="." valign="bottom">0.022</td></tr><tr><td align="left" valign="bottom"><italic>Mir130a</italic></td><td align="left" valign="bottom"><italic>mmu-miR-130a</italic></td><td align="char" char="." valign="bottom">25.2</td><td align="char" char="." valign="bottom">3.94</td><td align="char" char="." valign="bottom">0.046</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Putative targeting of the differentially expressed genes by the eight validated miRNAs (in <xref ref-type="fig" rid="fig1">Figure 1h</xref>).</title><p>This table lists the 174 differentially expressed genes putatively targeted by one or more discriminant miRNAs according to the in silico prediction analysis using four algorithms (TargetScan, Miranda, RNA22, and miRWalk). Crosses indicate a putative target predicted by three or four algorithms (score 3–4). i-OCLs: inflammatory osteoclasts; t-OCLs: tolerogenic osteoclasts.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Gene symbol</th><th align="left" valign="bottom" rowspan="2">-log(p-value)</th><th align="left" valign="bottom" rowspan="2">Fold change (log2)</th><th align="left" valign="bottom" colspan="4">i-OCLs miRNAs (score 3–4)</th><th align="left" valign="bottom" colspan="4">t-OCLs miRNAs (score 3–4)</th></tr><tr><th align="left" valign="bottom"><italic>Mir155</italic></th><th align="left" valign="bottom"><italic>Mir146b</italic></th><th align="left" valign="bottom"><italic>Mir342</italic></th><th align="left" valign="bottom"><italic>Mir151</italic></th><th align="left" valign="bottom"><italic>Mir185</italic></th><th align="left" valign="bottom"><italic>Mir674</italic></th><th align="left" valign="bottom"><italic>Mir26b</italic></th><th align="left" valign="bottom"><italic>Mir29a</italic></th></tr></thead><tbody><tr><td align="char" char="." valign="bottom"><italic>1810011H11Rik</italic></td><td align="char" char="." valign="bottom">2,78</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="char" char="." valign="bottom"><italic>5430427O19Rik</italic></td><td align="char" char="." valign="bottom">2,56</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="char" char="." valign="bottom"><italic>9930111J21Rik1</italic></td><td align="char" char="." valign="bottom">3,31</td><td align="char" char="." valign="bottom">–3,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>A530064D06Rik</italic></td><td align="char" char="." valign="bottom">3,67</td><td align="char" char="." valign="bottom">–4,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Abcc3</italic></td><td align="char" char="." valign="bottom">2,41</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Acpp</italic></td><td align="char" char="." valign="bottom">2,81</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Acvrl1</italic></td><td align="char" char="." valign="bottom">2,48</td><td align="char" char="." valign="bottom">–2,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Adap2</italic></td><td align="char" char="." valign="bottom">3,93</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ahrr</italic></td><td align="char" char="." valign="bottom">2,37</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Akt3</italic></td><td align="char" char="." valign="bottom">3,24</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Alox5</italic></td><td align="char" char="." valign="bottom">2,86</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Als2cl</italic></td><td align="char" char="." valign="bottom">3,45</td><td align="char" char="." valign="bottom">–4,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Aoah</italic></td><td align="char" char="." valign="bottom">4,41</td><td align="char" char="." valign="bottom">–4,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Apobec1</italic></td><td align="char" char="." valign="bottom">3,21</td><td align="char" char="." valign="bottom">–2,9</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Arhgap15</italic></td><td align="char" char="." valign="bottom">3,01</td><td align="char" char="." valign="bottom">–3,7</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Arhgap19</italic></td><td align="char" char="." valign="bottom">2,35</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Arhgef10l</italic></td><td align="char" char="." valign="bottom">2,80</td><td align="char" char="." valign="bottom">–2,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Arl4c</italic></td><td align="char" char="." valign="bottom">3,00</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Atf3</italic></td><td align="char" char="." valign="bottom">2,61</td><td align="char" char="." valign="bottom">–3,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Atp1a3</italic></td><td align="char" char="." valign="bottom">3,36</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>B430306N03Rik</italic></td><td align="char" char="." valign="bottom">3,14</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>B4galt6</italic></td><td align="char" char="." valign="bottom">2,90</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Bhlhe41</italic></td><td align="char" char="." valign="bottom">3,45</td><td align="char" char="." valign="bottom">–3,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Bst1</italic></td><td align="char" char="." valign="bottom">2,49</td><td align="char" char="." valign="bottom">–3,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Btg2</italic></td><td align="char" char="." valign="bottom">2,67</td><td align="char" char="." valign="bottom">–3,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>C3ar1</italic></td><td align="char" char="." valign="bottom">2,90</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>C5ar1</italic></td><td align="char" char="." valign="bottom">3,30</td><td align="char" char="." valign="bottom">–3,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Camk1d</italic></td><td align="char" char="." valign="bottom">2,47</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Ccl6</italic></td><td align="char" char="." valign="bottom">5,25</td><td align="char" char="." valign="bottom">–5,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cd28</italic></td><td align="char" char="." valign="bottom">2,56</td><td align="char" char="." valign="bottom">–1,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cd300lb</italic></td><td align="char" char="." valign="bottom">3,16</td><td align="char" char="." valign="bottom">–3,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Cd300ld</italic></td><td align="char" char="." valign="bottom">4,11</td><td align="char" char="." valign="bottom">–4,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cd36</italic></td><td align="char" char="." valign="bottom">4,26</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cd5l</italic></td><td align="char" char="." valign="bottom">3,43</td><td align="char" char="." valign="bottom">3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cd93</italic></td><td align="char" char="." valign="bottom">3,69</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Cdc42ep3</italic></td><td align="char" char="." valign="bottom">3,01</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cebpa</italic></td><td align="char" char="." valign="bottom">2,99</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Chst12</italic></td><td align="char" char="." valign="bottom">2,72</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Clec4a1</italic></td><td align="char" char="." valign="bottom">3,89</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Clec4n</italic></td><td align="char" char="." valign="bottom">3,02</td><td align="char" char="." valign="bottom">–3,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cmpk2</italic></td><td align="char" char="." valign="bottom">3,05</td><td align="char" char="." valign="bottom">–2,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cnr2</italic></td><td align="char" char="." valign="bottom">2,91</td><td align="char" char="." valign="bottom">–3,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Cybb</italic></td><td align="char" char="." valign="bottom">4,24</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Dab2</italic></td><td align="char" char="." valign="bottom">3,30</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Dapk1</italic></td><td align="char" char="." valign="bottom">2,44</td><td align="char" char="." valign="bottom">–1,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ddx58</italic></td><td align="char" char="." valign="bottom">3,39</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Dhrs3</italic></td><td align="char" char="." valign="bottom">3,35</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Dock1</italic></td><td align="char" char="." valign="bottom">2,35</td><td align="char" char="." valign="bottom">–1,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Dock2</italic></td><td align="char" char="." valign="bottom">2,65</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Dram1</italic></td><td align="char" char="." valign="bottom">2,98</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Dtx3l</italic></td><td align="char" char="." valign="bottom">3,00</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ednrb</italic></td><td align="char" char="." valign="bottom">3,79</td><td align="char" char="." valign="bottom">–3,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Elmsan1</italic></td><td align="char" char="." valign="bottom">2,86</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Entpd1</italic></td><td align="char" char="." valign="bottom">2,84</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Eps8</italic></td><td align="char" char="." valign="bottom">3,85</td><td align="char" char="." valign="bottom">–4,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Fabp5</italic></td><td align="char" char="." valign="bottom">3,23</td><td align="char" char="." valign="bottom">–2,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Fads1</italic></td><td align="char" char="." valign="bottom">4,20</td><td align="char" char="." valign="bottom">–3,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Fcgr4</italic></td><td align="char" char="." valign="bottom">3,58</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Frmd4b</italic></td><td align="char" char="." valign="bottom">2,92</td><td align="char" char="." valign="bottom">–2,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Gas7</italic></td><td align="char" char="." valign="bottom">2,43</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Gbp2</italic></td><td align="char" char="." valign="bottom">3,70</td><td align="char" char="." valign="bottom">–3,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Gcnt1</italic></td><td align="char" char="." valign="bottom">2,37</td><td align="char" char="." valign="bottom">–2,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ggta1</italic></td><td align="char" char="." valign="bottom">3,34</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Gna15</italic></td><td align="char" char="." valign="bottom">2,86</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Gng2</italic></td><td align="char" char="." valign="bottom">2,98</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Gpr162</italic></td><td align="char" char="." valign="bottom">4,13</td><td align="char" char="." valign="bottom">–4,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>H2-M3</italic></td><td align="char" char="." valign="bottom">2,70</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Hfe</italic></td><td align="char" char="." valign="bottom">5,45</td><td align="char" char="." valign="bottom">–3,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Hip1</italic></td><td align="char" char="." valign="bottom">2,71</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Hvcn1</italic></td><td align="char" char="." valign="bottom">3,48</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Id3</italic></td><td align="char" char="." valign="bottom">3,61</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ifi203</italic></td><td align="char" char="." valign="bottom">2,64</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Ifi204</italic></td><td align="char" char="." valign="bottom">3,08</td><td align="char" char="." valign="bottom">–2,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ifih1</italic></td><td align="char" char="." valign="bottom">4,04</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ifit3</italic></td><td align="char" char="." valign="bottom">2,82</td><td align="char" char="." valign="bottom">–2,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ifngr1</italic></td><td align="char" char="." valign="bottom">2,38</td><td align="char" char="." valign="bottom">–2,1</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Igf1</italic></td><td align="char" char="." valign="bottom">3,78</td><td align="char" char="." valign="bottom">–4,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Igfbp4</italic></td><td align="char" char="." valign="bottom">3,21</td><td align="char" char="." valign="bottom">–4,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ikbke</italic></td><td align="char" char="." valign="bottom">3,62</td><td align="char" char="." valign="bottom">–3,9</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Ikzf1</italic></td><td align="char" char="." valign="bottom">3,18</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Il7r</italic></td><td align="char" char="." valign="bottom">3,05</td><td align="char" char="." valign="bottom">–3,8</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Irf9</italic></td><td align="char" char="." valign="bottom">2,46</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Itgal</italic></td><td align="char" char="." valign="bottom">2,94</td><td align="char" char="." valign="bottom">–3,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Kctd12</italic></td><td align="char" char="." valign="bottom">2,63</td><td align="char" char="." valign="bottom">–2,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Kif3a</italic></td><td align="char" char="." valign="bottom">2,71</td><td align="char" char="." valign="bottom">–1,9</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Klf2</italic></td><td align="char" char="." valign="bottom">2,62</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Lamp2</italic></td><td align="char" char="." valign="bottom">2,45</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ldlrad3</italic></td><td align="char" char="." valign="bottom">2,71</td><td align="char" char="." valign="bottom">–3,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Limd2</italic></td><td align="char" char="." valign="bottom">3,05</td><td align="char" char="." valign="bottom">–2,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Lipa</italic></td><td align="char" char="." valign="bottom">2,53</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Lpar6</italic></td><td align="char" char="." valign="bottom">3,10</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Lpcat2</italic></td><td align="char" char="." valign="bottom">2,57</td><td align="char" char="." valign="bottom">–3,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ltbp2</italic></td><td align="char" char="." valign="bottom">2,53</td><td align="char" char="." valign="bottom">–3,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ly6e</italic></td><td align="char" char="." valign="bottom">3,96</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ly9</italic></td><td align="char" char="." valign="bottom">2,34</td><td align="char" char="." valign="bottom">–1,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Lyl1</italic></td><td align="char" char="." valign="bottom">3,48</td><td align="char" char="." valign="bottom">–3,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Lyz2</italic></td><td align="char" char="." valign="bottom">3,62</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Maf</italic></td><td align="char" char="." valign="bottom">3,59</td><td align="char" char="." valign="bottom">–4,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mafb</italic></td><td align="char" char="." valign="bottom">2,41</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Man2a2</italic></td><td align="char" char="." valign="bottom">3,96</td><td align="char" char="." valign="bottom">–2,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Map3k1</italic></td><td align="char" char="." valign="bottom">2,42</td><td align="char" char="." valign="bottom">–2,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Marcks</italic></td><td align="char" char="." valign="bottom">2,80</td><td align="char" char="." valign="bottom">–2,2</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mef2c</italic></td><td align="char" char="." valign="bottom">2,75</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mertk</italic></td><td align="char" char="." valign="bottom">2,70</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mgll</italic></td><td align="char" char="." valign="bottom">2,44</td><td align="char" char="." valign="bottom">–2,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mmp12</italic></td><td align="char" char="." valign="bottom">4,16</td><td align="char" char="." valign="bottom">–4,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Mpeg1</italic></td><td align="char" char="." valign="bottom">3,07</td><td align="char" char="." valign="bottom">–3,4</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ms4a6b</italic></td><td align="char" char="." valign="bottom">7,62</td><td align="char" char="." valign="bottom">–4,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>N4bp2l1</italic></td><td align="char" char="." valign="bottom">3,02</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Ncapg2</italic></td><td align="char" char="." valign="bottom">3,05</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Ncf1</italic></td><td align="char" char="." valign="bottom">4,43</td><td align="char" char="." valign="bottom">–4,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Nek6</italic></td><td align="char" char="." valign="bottom">2,46</td><td align="char" char="." valign="bottom">–4,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Neurl3</italic></td><td align="char" char="." valign="bottom">4,51</td><td align="char" char="." valign="bottom">–3,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Nlrp3</italic></td><td align="char" char="." valign="bottom">3,29</td><td align="char" char="." valign="bottom">–4,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Nrp1</italic></td><td align="char" char="." valign="bottom">2,36</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Oas1a</italic></td><td align="char" char="." valign="bottom">2,52</td><td align="char" char="." valign="bottom">–2,3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Osm</italic></td><td align="char" char="." valign="bottom">3,07</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>P2rx7</italic></td><td align="char" char="." valign="bottom">3,53</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Pacs1</italic></td><td align="char" char="." valign="bottom">4,16</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Parp14</italic></td><td align="char" char="." valign="bottom">2,93</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Peli2</italic></td><td align="char" char="." valign="bottom">4,98</td><td align="char" char="." valign="bottom">–2,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Pgap1</italic></td><td align="char" char="." valign="bottom">3,22</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Pim1</italic></td><td align="char" char="." valign="bottom">2,93</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Pld4</italic></td><td align="char" char="." valign="bottom">5,19</td><td align="char" char="." valign="bottom">–4,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Plxnc1</italic></td><td align="char" char="." valign="bottom">4,24</td><td align="char" char="." valign="bottom">–4,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Pmp22</italic></td><td align="char" char="." valign="bottom">2,98</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Ppbp</italic></td><td align="char" char="." valign="bottom">2,90</td><td align="char" char="." valign="bottom">5,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ptgir</italic></td><td align="char" char="." valign="bottom">3,30</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ptgs1</italic></td><td align="char" char="." valign="bottom">3,71</td><td align="char" char="." valign="bottom">–4,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Rab3il1</italic></td><td align="char" char="." valign="bottom">3,19</td><td align="char" char="." valign="bottom">–3,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Rab8b</italic></td><td align="char" char="." valign="bottom">2,85</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Rcsd1</italic></td><td align="char" char="." valign="bottom">3,74</td><td align="char" char="." valign="bottom">–3,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Rnasel</italic></td><td align="char" char="." valign="bottom">2,62</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Rnf150</italic></td><td align="char" char="." valign="bottom">4,58</td><td align="char" char="." valign="bottom">–2,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Rsad2</italic></td><td align="char" char="." valign="bottom">2,53</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Rxra</italic></td><td align="char" char="." valign="bottom">2,59</td><td align="char" char="." valign="bottom">–1,9</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>S1pr1</italic></td><td align="char" char="." valign="bottom">3,26</td><td align="char" char="." valign="bottom">–3,6</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Sash1</italic></td><td align="char" char="." valign="bottom">3,01</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Sash3</italic></td><td align="char" char="." valign="bottom">3,21</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Sdc3</italic></td><td align="char" char="." valign="bottom">2,38</td><td align="char" char="." valign="bottom">–2,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Sepp1</italic></td><td align="char" char="." valign="bottom">3,53</td><td align="char" char="." valign="bottom">–4,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Sgpp1</italic></td><td align="char" char="." valign="bottom">2,38</td><td align="char" char="." valign="bottom">–2,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Sidt2</italic></td><td align="char" char="." valign="bottom">2,64</td><td align="char" char="." valign="bottom">–2,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Six1</italic></td><td align="char" char="." valign="bottom">3,60</td><td align="char" char="." valign="bottom">–5,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Slamf7</italic></td><td align="char" char="." valign="bottom">4,94</td><td align="char" char="." valign="bottom">–4,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Slamf8</italic></td><td align="char" char="." valign="bottom">3,05</td><td align="char" char="." valign="bottom">–2,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Slc7a11</italic></td><td align="char" char="." valign="bottom">3,08</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Slc9a3r1</italic></td><td align="char" char="." valign="bottom">2,94</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Slfn5</italic></td><td align="char" char="." valign="bottom">4,24</td><td align="char" char="." valign="bottom">–2,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Slfn8</italic></td><td align="char" char="." valign="bottom">2,76</td><td align="char" char="." valign="bottom">–3,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Snx24</italic></td><td align="char" char="." valign="bottom">2,99</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Snx30</italic></td><td align="char" char="." valign="bottom">2,79</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Stat2</italic></td><td align="char" char="." valign="bottom">2,76</td><td align="char" char="." valign="bottom">–1,8</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Stom</italic></td><td align="char" char="." valign="bottom">2,60</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Susd3</italic></td><td align="char" char="." valign="bottom">2,76</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tanc2</italic></td><td align="char" char="." valign="bottom">2,65</td><td align="char" char="." valign="bottom">–3,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tifa</italic></td><td align="char" char="." valign="bottom">2,53</td><td align="char" char="." valign="bottom">–2,5</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tle3</italic></td><td align="char" char="." valign="bottom">4,70</td><td align="char" char="." valign="bottom">–3,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tlr13</italic></td><td align="char" char="." valign="bottom">4,27</td><td align="char" char="." valign="bottom">–4,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tmem154</italic></td><td align="char" char="." valign="bottom">3,16</td><td align="char" char="." valign="bottom">–5,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Tmem176a</italic></td><td align="char" char="." valign="bottom">4,09</td><td align="char" char="." valign="bottom">–5,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tmem176b</italic></td><td align="char" char="." valign="bottom">4,13</td><td align="char" char="." valign="bottom">–4,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tmem229b</italic></td><td align="char" char="." valign="bottom">2,75</td><td align="char" char="." valign="bottom">–1,9</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Tmem71</italic></td><td align="char" char="." valign="bottom">4,32</td><td align="char" char="." valign="bottom">–4,7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tnfaip8l2</italic></td><td align="char" char="." valign="bottom">2,54</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Tnfrsf26</italic></td><td align="char" char="." valign="bottom">3,50</td><td align="char" char="." valign="bottom">–4,4</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Trim30a</italic></td><td align="char" char="." valign="bottom">2,41</td><td align="char" char="." valign="bottom">–1,9</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Trim30d</italic></td><td align="char" char="." valign="bottom">3,73</td><td align="char" char="." valign="bottom">–4,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ugcg</italic></td><td align="char" char="." valign="bottom">2,90</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Usp18</italic></td><td align="char" char="." valign="bottom">4,07</td><td align="char" char="." valign="bottom">–3,0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Wls</italic></td><td align="char" char="." valign="bottom">2,43</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Ypel3</italic></td><td align="char" char="." valign="bottom">2,39</td><td align="char" char="." valign="bottom">–1,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Zcchc24</italic></td><td align="char" char="." valign="bottom">3,30</td><td align="char" char="." valign="bottom">–3,2</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>Zfhx3</italic></td><td align="char" char="." valign="bottom">3,46</td><td align="char" char="." valign="bottom">–2,4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Zfp36l1</italic></td><td align="char" char="." valign="bottom">2,36</td><td align="char" char="." valign="bottom">–2,1</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td></tr><tr><td align="left" valign="bottom"><italic>Zfp608</italic></td><td align="char" char="." valign="bottom">2,38</td><td align="char" char="." valign="bottom">–2,6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/><td align="left" valign="bottom">X</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>These data strongly suggest that CLRs could play an important role in the specific properties of i-OCLs and t-OCLs. Analysis of the RNAseq data for the expression of genes involved in the CLR and TLR signaling pathways confirmed major differences between t-OCLs and i-OCLs (<xref ref-type="fig" rid="fig1">Figure 1j</xref>). Validation by flow cytometry analysis of mature multinucleated OCLs confirmed that the proportion of OCLs expressing Dectin-1, Mincle, and Tlr2, but not Dectin-2, was significantly higher in i-OCLs compared to t-OCLs (<xref ref-type="fig" rid="fig1">Figure 1k</xref>). We also analyzed their expression in OCL progenitors. The proportion of cells expressing Dectin-1, Mincle, and Tlr2 was much higher in CD11c<sup>+</sup> BM-derived DCs than in BM CD11b<sup>+</sup> MNs, and the proportion of i-OCL progenitors expressing Dectin-2 was lower than for the other markers (<xref ref-type="fig" rid="fig1">Figure 1l</xref>).</p></sec><sec id="s2-2"><title>The probiotic yeast <italic>Saccharomyces boulardii</italic> CNCM I-745 protects from osteoporosis-induced bone loss in vivo</title><p>The herein investigated OCL populations were derived from purified progenitor cells which are a powerful approach to identify major differences (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>), while in vivo, OCLs arise from a mixture of different BM progenitors whose proportions are depending on the pathophysiological conditions (<xref ref-type="bibr" rid="bib35">Madel et al., 2019</xref>). Thus, we compared BM-derived OCLs from OVX-induced osteoporotic mice in which the proportion of i-OCL increases (<xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>) to OCLs derived from SHAM mice. FACS analysis revealed higher proportions of Dectin-1<sup>+</sup> and Tlr2<sup>+</sup> OCLs, in OCLs generated from OVX mice compared to those from SHAM mice, while the proportion of Mincle<sup>+</sup> OCLs was not significantly altered (<xref ref-type="fig" rid="fig2">Figure 2a</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The probiotic yeast <italic>Saccharomyces boulardii</italic> (<italic>Sb)</italic> has beneficial effects on bone loss in osteoporosis.</title><p>(<bold>a</bold>) Quantification (mean ± SD) of FACS analysis of Dectin-1<sup>+</sup>, Tlr2<sup>+</sup>, and Mincle<sup>+</sup> mature osteoclasts (OCLs; ≥three nuclei, gated as shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>, differentiated from the bone marrow of SHAM and ovariectomized (OVX)) mice, 6 weeks after surgery. (<bold>b</bold>) Schematic representation of the experimental procedure. Uterus and body weight were measured to control the quality of ovariectomy (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–b</xref>). (<bold>c</bold>) Representative microcomputed tomography images of femurs from SHAM and OVX mice ± <italic>Sb</italic> administration. (<bold>d</bold>) Histograms indicate mean ± SD of trabecular bone volume fraction, trabecular number, separation, and thickness. Cortical parameters were also measured (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c</xref>). (<bold>e</bold>) Histological analysis of OCLs using TRAcP staining (in purple) on tibias from SHAM and OVX mice treated or not with <italic>Sb</italic>. Scale bars: 100 µm. (<bold>f</bold>) Histogram indicates the mean ± SD of TRAcP<sup>+</sup> area per bone surface for each condition. Three images of four to five biological replicates were analyzed. Osterix<sup>+</sup> and Sost<sup>+</sup> cells were also analyzed (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a–d</xref>). The mineralization capacity of osteoblasts was also analyzed in vitro in the presence of <italic>Sb</italic>-conditioned medium (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2e</xref>). (<bold>g</bold>) Serum cross-linked C-telopeptides of type I collagen (CTX) were measured by ELISA (n≥5 biological replicates per condition). *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Cortical bone parameters of SHAM and OVX mice.</title><p>(<bold>a</bold>) Weight of the uteri of ovariectomized (OVX) and SHAM mice treated or not with <italic>Saccharomyces boulardii</italic> (<italic>Sb)</italic> (mean ± SD). (<bold>b</bold>) Body weight of the mice in the different groups, measured the day of sacrifice (mean ± SD). Data show no differences between yeast-treated mice and control mice in each group (SHAM and OVX). (<bold>c</bold>) Histograms indicate mean ± SD of cortical bone volume (BV), cortical bone surface/bone volume (BS/BV), and cortical thickness. **** p&lt;0.0001; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Effect of <italic>Sb</italic> treatment on osteoblasts and osteocytes.</title><p>(<bold>a–d</bold>) Histological analysis of the tibia of SHAM and ovariectomized (OVX) mice treated or not with <italic>Saccharomyces boulardii</italic> (<italic>Sb)</italic>. (<bold>a–b</bold>) Osteoblasts were identified as Osterix-expressing cells attached to the bone surface, and (<bold>c–d</bold>) osteocytes were identified by their expression of Sost. (<bold>b, d</bold>) Histograms represent the enumeration (mean ± SD) of the cells for one image per replicate (n=5 mice per group). Scale bars: 100 µm. (<bold>e</bold>) In vitro mineralization capacity as measured by alizarin coloration of mineralized nodules deposited in vitro by osteoblasts treated or not with the indicated proportion of medium conditioned by <italic>Sb</italic> (mean ± SD). *p&lt;0.05; **p&lt;0.01; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig2-figsupp2-v1.tif"/></fig></fig-group><p>These PRRs share the capacity to sense fungi and control responses to pathogenic or commensal gut mycobiome (<xref ref-type="bibr" rid="bib31">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Sancho and Reis e Sousa, 2012</xref>). Therefore, we treated SHAM and OVX mice by oral gavage with the probiotic yeast <italic>Sb</italic> (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). As expected, OVX mice showed atrophy of the uterus and their body weight increased compared to SHAM control mice, which was not affected by treatment with <italic>Sb</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–b</xref>). Micro-computed tomographic (μCT) analysis revealed that <italic>Sb</italic>-treated OVX mice displayed reduced trabecular bone loss, as assessed by a significantly higher trabecular bone volume fraction (BV/TV) and trabecular number and less significant reduction in trabecular separation compared to untreated OVX mice (<xref ref-type="fig" rid="fig2">Figure 2c–d</xref>). Furthermore, administration of <italic>Sb</italic> resulted in a reduction of TRAcP<sup>+</sup> OCL surface per bone surface in OVX mice (<xref ref-type="fig" rid="fig2">Figure 2e–f</xref>) and a significantly reduced serum level of cross-linked C-telopeptides of type I collagen (CTX), confirming a decrease in OCL activity (<xref ref-type="fig" rid="fig2">Figure 2g</xref>). Importantly, <italic>Sb</italic> treatment did not affect cortical parameters (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>), which could be due to a too short treatment period, as suggested in previous studies using bacterial probiotics (<xref ref-type="bibr" rid="bib38">McCabe et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Britton et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Lawenius et al., 2022</xref>) or to a site-specific response to yeast derivates. It had no effect on the number of osteoblasts and osteocytes in vivo (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a–d</xref>) and on the mineralization capacity of osteoblasts in vitro (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2e</xref>).</p><p>We then checked whether <italic>Sb</italic> treatment affects inflammatory parameters and microbiota metabolites that are known to influence bone remodeling (<xref ref-type="bibr" rid="bib64">Zaiss et al., 2019</xref>). Evaluation of the gut barrier integrity by fluorescein isothiocyanate (FITC)-dextran assay showed a reduction in serum dextran concentration in <italic>Sb-</italic>treated OVX mice to the level observed in SHAM mice (<xref ref-type="fig" rid="fig3">Figure 3a</xref>) confirming the protective effect of <italic>Sb</italic> on the intestinal barrier as already reported in other pathological contexts (<xref ref-type="bibr" rid="bib57">Terciolo et al., 2019</xref>). Modifications in the gut microbiome were evaluated by dosage of serum concentrations of metabolites produced by commensal bacteria such as propionate and butyrate, two major short chain fatty acids (SCFA) as well as lactate produced by lactic acid bacteria (LAB). Serum propionate, butyrate, and lactate were reduced in OVX mice, and treatment with <italic>Sb</italic> reversed this decrease, although not reaching statistical significance for lactate and butyrate (<xref ref-type="fig" rid="fig3">Figure 3b–d</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Saccharomyces boulardii (Sb)</italic> reduces inflammatory parameters in osteoporosis.</title><p>(<bold>a</bold>) Integrity of the intestinal barrier permeability was analyzed by fluorometry on the serum of mice that received oral gavage of dextran-fluorescein isothiocyanate 1 hr before sacrifice (n=4–5 biological replicates) (mean ± SD). (<bold>b–d</bold>) Concentrations (mean ± SD) of (<bold>b</bold>) propionate, (<bold>c</bold>) butyrate, and (<bold>d</bold>) lactate were measured by chromatography in the serum of SHAM and ovariectomized (OVX) mice treated or not with Sb (n=4 biological replicate per group). *p&lt;0.05; **p&lt;0.01. (<bold>e</bold>) FACS analysis of Tnf-α-producing CD4<sup>+</sup> T cells in the bone marrow (BM) of OVX and SHAM control mice with or without <italic>Sb</italic> treatment (n=8–10 biological replicate per group). (<bold>f</bold>) Proportion of mature Cx3cr1<sup>+</sup> BM-derived OCLs (≥three nuclei, gated as shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>) from SHAM and OVX mice treated or not with <italic>Sb</italic> (n=10–14 biological replicate per group) was determined by FACS analysis. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig3-v1.tif"/></fig><p>Interestingly, in <italic>Sb</italic>-treated OVX mice, we also observed a decreased proportion of BM CD4<sup>+</sup> Tnf-α-producing T cells that have been reported to be responsible for increased osteoclastogenesis in OVX mice (<xref ref-type="bibr" rid="bib4">Cenci et al., 2000</xref>; <xref ref-type="fig" rid="fig3">Figure 3e</xref>). Lastly, we evaluated i-OCL differentiation by analyzing mature BM-derived OCLs for their expression of Cx3cr1, the previously described marker for i-OCLs (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>). In <italic>Sb</italic>-treated OVX mice, the proportion of Cx3cr1<sup>+</sup> i-OCLs was significantly reduced compared to non-treated OVX mice, while there was no alteration of Cx3cr1<sup>+</sup> OCLs in SHAM mice (<xref ref-type="fig" rid="fig3">Figure 3f</xref>).</p></sec><sec id="s2-3"><title>Stimulation of TLRs and CLRs influences i-OCL differentiation</title><p>Our results showed that the beneficial effect of <italic>Sb</italic> in OVX mice was in part due to a systemic effect on inflammatory parameters responsible for pathological osteoclastogenesis. However, yeast derivatives such as ß-glucans are known to translocate to the blood and organs through the gut barrier (<xref ref-type="bibr" rid="bib21">Isnard et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Rice et al., 2005</xref>) and can therefore directly affect cells expressing PRR that recognize them. Thus, we determined the direct effect of agonists of these receptors on the differentiation of t-OCLs and i-OCLs. We used curdlan and zymosan as Dectin-1 and Tlr2 agonists and glucosyl-6-tetradecyloctadecanoate (GlcC<sub>14</sub>C<sub>18</sub>, a synthetic C6-branched glycolipid) to stimulate Mincle. The formation of t-OCLs from BM CD11b<sup>+</sup> cells was not affected by any of these agonists (<xref ref-type="fig" rid="fig4">Figure 4a–c</xref>), consistent with their low expression of Dectin-1, Tlr2, and Mincle receptors (<xref ref-type="fig" rid="fig1">Figure 1k–l</xref>). In contrast, curdlan, zymosan, and GlcC<sub>14</sub>C<sub>18</sub> dramatically inhibited the differentiation of BM-derived DCs into i-OCLs (<xref ref-type="fig" rid="fig4">Figure 4a–c</xref>). This effect was not due to an increased apoptosis of the cells in the presence of the agonists (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a–d</xref>). To confirm the involvement of Dectin-1, Tlr2, and Mincle in these effects, we used neutralizing antibodies and siRNA. Anti-Dectin-1 and anti-Mincle antibodies reversed the inhibitory effect of curdlan and GlcC<sub>14</sub>C<sub>18</sub>, respectively, on i-OCL formation compared to the control isotype (<xref ref-type="fig" rid="fig4">Figure 4d–e</xref>). <italic>Tlr2</italic> siRNA decreased the expression level of membrane Tlr2, as expected (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1e</xref>) and was able to abrogate the decrease of i-OCL differentiation induced by curdlan but not by zymosan (<xref ref-type="fig" rid="fig4">Figure 4f</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Implication of Tlr2, Dectin-1, and Mincle in the differentiation of inflammatory osteoclasts (i-OCLs).</title><p>(<bold>a–c</bold>) Quantification of the differentiation of tolerogenic OCLs (t-OCLs) and i-OCLs in the presence of indicated concentrations of curdlan, zymosan, and GlcC<sub>14</sub>C<sub>18</sub>. Upper panels: TRAcP<sup>+</sup> cells with three or more nuclei were counted as OCLs. Histogram indicates the mean ± SD of the OCL normalized to the control condition (0 ng/mL agonist). Bottom panels: representative image of TRAcP staining for the control (without agonist) and agonist-treated i-OCLs at the indicated concentration. Quantification of cells viability in the presence of the agonists was also performed by FACS analysis (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a–d</xref>). (<bold>d-e</bold>) TRAcP staining and quantification of OCLs (TRAcP<sup>+</sup> cells ≥three nuclei) differentiated in the presence of control isotypes or blocking antibodies against (<bold>d</bold>) Dectin-1 and (<bold>e</bold>) Mincle. (<bold>f</bold>) Quantification of i-OCLs differentiated in the presence of control siRNA or siRNA targeting <italic>Tlr2</italic>. Level of Tlr2 expression in the presence and absence of siRNAs was evaluated by FACS (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1e</xref>). (<bold>g</bold>) OCL activity was evaluated by seeding bone marrow (BM)-derived dendritic cells on plates coated with resorbable matrix. After i-OCLs started to fuse (day 3 of differentiation), the different agonists were added at the following concentration: curdlan, 50 ng/mL; zymosan, 50 ng/mL, GlcC<sub>14</sub>C<sub>18</sub>, 1000 ng/mL. Resorbed area was quantified after 3 days. Evaluation of the effect of the agonists on t-OCL activity was also analyzed (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1f</xref>). Specific analysis of the effect of Mincle stimulation on OCL formation was assessed using <italic>Clec4e</italic>-KO mice (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). (<bold>h</bold>) Enumeration of in vitro differentiated OCLs from BM cells of OVX and SHAM mice in the presence of indicated concentrations of curdlan, zymosan, and GlcC<sub>14</sub>C<sub>18</sub> (Glc). TRAcP<sup>+</sup> cells with three or more nuclei were counted as OCLs (n=8–11). *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Effects of agonists on cell viability and t-OCL activity.</title><p>(<bold>a–d</bold>) Monocytes (MN) or dendritic cells (DC) were cultured in osteoclast differentiation medium in the absence (Ctl) or presence of curdlan (50 ng/mL), zymosan (50 ng/mL), GlcC<sub>14</sub>C<sub>18</sub> (1000 ng/mL), or <italic>Saccharomyces boulardii</italic> (-conditioned medium 25%). Histograms indicate mean ± SD of live cells (annexin-V<sup>neg</sup> propidium iodide<sup>neg</sup>) mesured by FACS in (<bold>a–b</bold>) MN and (<bold>c–d</bold>) DC after (<bold>a–c</bold>) 24 hr and (<bold>b–d</bold>) 48 hr of incubation with the agonists. (<bold>e</bold>) FACS analysis of the level of expression of Tlr2 in inflammatory osteoclast (OCL) progenitors in the presence of control siRNA or siRNA targeting <italic>Tlr2</italic>. (<bold>f</bold>) Activity of MN-OCL /tolerogenic OCLs was evaluated on plates coated with resorbable matrix. After OCLs started to fuse (day 3 of differentiation), the different agonists were added at the following concentration: curdlan, 50 ng/mL; GlcC<sub>14</sub>C<sub>18</sub>, 1000 ng/mL. When indicated, anti-TLR2 (aTLR2) or anti-Mincle (aMincle) antibodies (10 µg/mL) were also added. Resorbed area was quantified after 3 days. ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Bone phenotype and OCL differentiation in <italic>Clec4e</italic> deficient mice.</title><p>(<bold>a</bold>) Microcomputed tomography analysis on distal femurs <italic>Clec4e</italic><sup>−/−</sup> and <italic>Clec4e</italic> <sup>+/+</sup> mice. Histograms indicate mean ± SD of bone volume fraction (BV/TV), trabecular thickness (TbTh), trabecular number (TbN), and trabecular separation (TbSp). (<bold>b</bold>) Quantification of the differentiation of osteoclasts (OCLs) from total bone marrow (BM) cells, BM-monocyte cells (MNs) and BM-derived dendritic cells (DCs) from <italic>Clec4e</italic><sup>−/−</sup> and <italic>Clec4e</italic><sup>+/+</sup> mice. TRAcP<sup>+</sup> cells with three or more nuclei were counted as OCLs. (<bold>c</bold>) Quantification of the differentiation of inflammatory OCLs (DC-derived OCLs) from <italic>Clec4e</italic><sup>−/−</sup> and <italic>Clec4e</italic> <sup>+/+</sup> mice in the presence of the indicated concentration of GlcC<sub>14</sub>C<sub>18</sub>. TRAcP<sup>+</sup> cells with three or more nuclei were counted as OCLs. *p&lt;0.05; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig4-figsupp2-v1.tif"/></fig></fig-group><p>These data revealed that Dectin-1, Tlr2, and Mincle activation specifically inhibits the formation of i-OCLs without affecting t-OCLs. Additionally, we performed in vitro assays to assess the effect of these agonists on mature i-OCL activity. Our results revealed that, in addition to blocking i-OCL differentiation, agonists of these receptors also reduced their capacity to degrade mineralized matrix (<xref ref-type="fig" rid="fig4">Figure 4g</xref>), whereas they do not affect the activity of t-OCLs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1f</xref>).</p><p>In line with the aforementioned results, the Dectin-1 and Tlr2 agonists (curdlan and zymosan) also strongly reduced the differentiation of OCLs derived from BM cells of OVX mice in vitro, while they had no significant effect on the differentiation of OCLs generated from SHAM control mice (<xref ref-type="fig" rid="fig4">Figure 4h</xref>). However, GlcC<sub>14</sub>C<sub>18</sub> reduced OCL differentiation of progenitors from OVX mice but also from SHAM mice (<xref ref-type="fig" rid="fig4">Figure 4h</xref>), according to the equivalent expression level of Mincle in these cells (<xref ref-type="fig" rid="fig2">Figure 2a</xref>).</p><p>The inhibition of the differentiation of i-OCL by a Mincle agonist was contrasting with a recent publication showing that <italic>Clec4e<sup>−/−</sup></italic> mice deficient in Mincle have increased bone mass and that sensing of necrotic osteocytes by Mincle increases OCL differentiation (<xref ref-type="bibr" rid="bib2">Andreev et al., 2020</xref>). Accordingly, using µCT analysis, we observed the same increase in BV/TV, trabecular number, and trabecular thickness in <italic>Clec4e</italic> KO mice compared to controls, as already demonstrated (<xref ref-type="bibr" rid="bib2">Andreev et al., 2020</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a</xref>). However, in vitro assays revealed that BM cells, BM-DCs, and BM-MNs from <italic>Clec4e<sup>−/−</sup></italic> mice differentiate into OCLs at least as efficiently as cells from controls (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b</xref>), contrasting with data from the literature (<xref ref-type="bibr" rid="bib2">Andreev et al., 2020</xref>), which could be explained by different protocols used for in vitro OCL differentiation. Moreover, inhibition of i-OCL differentiation by GlcC<sub>14</sub>C<sub>18</sub> was decreased in cells from <italic>Clec4e<sup>−/−</sup></italic> compared to <italic>Clec4e</italic><sup>+/+</sup> mice confirming that Mincle is involved in this inhibition (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c</xref>). These data revealed that implication of Mincle in OCL differentiation is much more complex than expected.</p><p>Downstream signaling of Dectin-1 and Mincle largely involves activation of the spleen tyrosine kinase, Syk, which is also required for the differentiation and activity of OCLs (<xref ref-type="bibr" rid="bib40">Mócsai et al., 2004</xref>). Accordingly, we found that BM-derived DCs from <italic>CD11cΔSyk</italic> mice that have selective depletion of <italic>Syk</italic> in CD11c<sup>+</sup> cells (<xref ref-type="bibr" rid="bib20">Iborra et al., 2012</xref>) failed to differentiate into OCLs (<xref ref-type="fig" rid="fig5">Figure 5a</xref>), indicating that <italic>Syk</italic> expression by DCs is required for i-OCL formation. As expected, FACS analysis showed that addition of curdlan to the OCL differentiation medium rapidly induced Syk phosphorylation (<xref ref-type="fig" rid="fig5">Figure 5b</xref>), which was followed at 24 hr by an increased proportion of MHC-II<sup>+</sup> and CD80<sup>+</sup>CD86<sup>+</sup> DCs, revealing the maturation of BM-derived DCs (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). This treatment simultaneously reduced the proportion of RANK<sup>+</sup> cells expressing Csf1r (CD115) and FcgRII/III (CD16/32), all required for OCL differentiation (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). Furthermore, it also downregulated the expression of <italic>Syk</italic>, as well as its downstream targets <italic>Nfatc1</italic> and <italic>Ctsk</italic> (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). These results show that despite a rapid activation of Syk in BM-DCs treated with M-csf and Rank-L upon addition of curdlan, <italic>Syk</italic> expression decreases with time, as previously shown (<xref ref-type="bibr" rid="bib62">Yamasaki et al., 2014</xref>), as well as the capacity of BM-DCs to differentiate into i-OCLs.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Curdlan alters the capacity of dendritic cells (DCs) to differentiate into inflammatory osteoclasts (OCLs).</title><p>(<bold>a</bold>) Quantification of differentiation of inflammatory OCLs from <italic>CD11cΔSyk</italic> and control mice (n=9 and 6 biological replicates, respectively). (<bold>b</bold>) Flow cytometry analysis of spleen tyrosine kinase (Syk) phosphorylation after 15 min of stimulation with 100 ng/mL of curdlan on bone marrow (BM)-derived DCs cultured. The right panel shows the increase in the mean fluorescence intensity revealing increased Syk phophorylation (n=4 biological replicates). (<bold>c–d</bold>) FACS plots and quantification (mean ± SD) of the expression of (<bold>c</bold>) MHC-II, CD80, and CD86; and (<bold>d</bold>) CD115 (Csfr1), Rank, and CD16/32 (FcgrII/III) on BM-DCs (n=4 biological replicates per group) cultured in osteoclast differentiation medium and stimulated or not for 24 hr with the indicated curdlan concentrations (<bold>e</bold>) Quantitative real-time PCR analysis of the expression of <italic>Syk</italic>, <italic>Nfatc1,</italic> and <italic>Ctsk</italic> on BM-DCs cultured in osteoclast differentiation medium and stimulated or not for 72 hr with the indicated curdlan concentrations. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig5-v1.tif"/></fig><p>To investigate whether yeast probiotics have the same effect as the PRR agonists on the differentiation of i-OCLs, we used <italic>Sb-</italic>conditioned medium (<italic>Sb</italic>-CM). <italic>Sb</italic>-CM completely blocked the differentiation of i-OCL progenitors while it did not affect the formation of t-OCLs, except at very high concentrations (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). This inhibitory effect was not associated with an increase in cell apoptosis (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). Moreover, <italic>Sb</italic>-CM also reduced the resorption capacity of OCLs in vitro (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). Next, we addressed the involvement of Dectin-1, Tlr2, and Mincle in the inhibitory effect of <italic>Sb</italic>-CM on i-OCLs as described above. While <italic>Tlr2</italic>-siRNA had no effect (<xref ref-type="fig" rid="fig6">Figure 6d</xref>), anti-Dectin-1 and anti-Mincle blocking antibodies completely abrogated the inhibitory effect of <italic>Sb</italic>-CM on the differentiation of i-OCLs, demonstrating the prominent role of these receptors in mediating the effect of <italic>Sb</italic> on inflammatory osteoclastogenesis (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). Moreover, as curdlan, <italic>Sb-</italic>CM strongly stimulated BM-DC maturation (<xref ref-type="fig" rid="fig6">Figure 6f</xref>) while it dramatically decreased the proportion of Rank<sup>+</sup> Csf1r<sup>+</sup> (CD115<sup>+</sup>) and FcgRII/III<sup>+</sup> (CD16/32<sup>+</sup>) cells representing OCL progenitors (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). These results revealed that derivatives from <italic>Sb</italic> recognized by PRRs, such as ß-glucans, interfere with the capacity of BM-derived DCs to differentiate into i-OCLs and with the activity of these OCLs.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The probiotic yeast <italic>Saccharomyces boulardii</italic> (<italic>Sb)</italic> modulates the differentiation of inflammatory osteoclasts (i-OCLs).</title><p>(<bold>a</bold>) Quantification of differentiated tolerogenic OCLs (t-OCLs) and i-OCLs in the presence of indicated concentrations of <italic>Sb</italic>-conditioned medium (<italic>Sb</italic>-CM). (<bold>b</bold>) Apotosis of OCL progenitors (monocyte cells [MNs] and dendritic cells [DCs]) cultured in OCL differentiation medium in the absence (Control) or presence of <italic>Sb</italic>-CM (25%) was measured by FACS. Histograms indicate mean ± SD of live cells (annexin-V<sup>neg</sup> propidium iodide<sup>neg</sup>) after 24 hr and 48 hr. (<bold>c</bold>) OCL activity was evaluated by on plates coated with resorbable matrix by adding <italic>Sb</italic>-CM (25%) when OCL fusion is starting (day 3 of differentiation). Resorbed area was quantified 3 days after addition of <italic>Sb</italic>-CM. Control panels are the same as in <xref ref-type="fig" rid="fig4">Figure 4g</xref> because the experiments were performed together. (<bold>d</bold>) Differentiation of i-OCLs was performed in the presence of control siRNA or siRNA, targeting <italic>Tlr2</italic> in the absence or presence of <italic>Sb</italic>-CM. (<bold>e</bold>) Differentiation of i-OCLs was performed in the presence of blocking antibodies for Dectin-1 and Mincle in the absence or presence of <italic>Sb</italic>-CM. For all experiments, TRAcP<sup>+</sup> multinucleated cells with ≥three nuclei were considered as OCLs and enumerated after 6 days of culture. (<bold>f–g</bold>) FACS plots and quantification (mean ± SD) of the expression of (<bold>f</bold>) MHC-II, CD80, and CD86; and (<bold>g</bold>) CD115 (Csfr1), Rank, and CD16/32 (FcgrII/III) on BM-DCs (n=4 biological replicates) cultured in osteoclast differentiation medium and stimulated or not for 24 hr with the indicated % of <italic>Sb</italic>-CM. The control panels (without <italic>Sb</italic>) are identical to those of <xref ref-type="fig" rid="fig5">Figure 5c–d</xref> as the experiments were performed together. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, non-significant differences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The present study demonstrates that i-OCLs and t-OCLs are two distinct OCL populations with specific molecular signatures that differ in their preferential use of differentiation pathways and their capacity to sense the environment through the PRRs Dectin-1, Tlr2, and Mincle. Based on these specificities, we could show that targeting these receptors reduces bone loss in OVX mice and inhibits specifically the differentiation of i-OCLs while sparing t-OCLs.</p><p>OCL heterogeneity has been neglected for a long time, and the mechanisms regulating the emergence and function of i-OCLs are still largely unknown. Our transcriptomic profiling shows that, while being comparable in their expression of bone resorption-associated genes, t-OCLs and i-OCLs differ in their expression of genes associated with immune responses, which provides additional evidence for their previously reported divergent immune properties (<xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>). It also highlights differences in genes related to OCL differentiation. Osteoclastogenesis is regulated by two main pathways, the classical Rank-associated and the co-stimulatory Ig-like receptor-associated pathways, both of which are required to promote OCL differentiation (<xref ref-type="bibr" rid="bib16">Humphrey and Nakamura, 2016</xref>; <xref ref-type="bibr" rid="bib26">Koga et al., 2004</xref>; <xref ref-type="bibr" rid="bib54">Seeling et al., 2013</xref>). Increased Rank-L levels as well as stimulation of FcγR and ITAM signaling are involved in pathological bone resorption in rheumatic diseases such as rheumatoid arthritis (<xref ref-type="bibr" rid="bib15">Herman et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Ochi et al., 2007</xref>). However, to date these pathways have not been described to be preferentially used by specific populations of OCLs. Here, we show that the implication of the co-stimulatory pathway in diseases associated with high bone resorption could be linked to its upregulation during i-OCL differentiation, which suggests that specific targeting of this pathway and its related molecules could limit inflammatory bone loss with a minimal impact on OCLs involved in physiological bone remodeling.</p><p>Remarkably, Tlr2, Dectin-1, and Mincle are increased in i-OCLs and OCLs from OVX mice compared to t-OCLs and to those from SHAM mice. These receptors are expressed in myeloid cells and sense microbial structures from bacteria, fungi, or parasites, including lipoproteins, glycoproteins, peptidoglycan for Tlr2, β-glucans for Dectin-1 and Tlr2, and α-mannose for Mincle (<xref ref-type="bibr" rid="bib51">Sancho and Reis e Sousa, 2012</xref>; <xref ref-type="bibr" rid="bib53">Savva and Roger, 2013</xref>). Moreover, they interact with each other and with Fcγ receptors for the induction of inflammatory responses (<xref ref-type="bibr" rid="bib12">Gantner et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Sato et al., 2003</xref>). Very few studies have investigated the effect of microbial β-glucans and α-mannose on osteoclastogenesis. Tlr2 stimulation was shown to reduce osteoclastogenesis from non-committed OCL progenitors but to increase OCL survival and differentiation of Rank-L-primed pre-OCLs (<xref ref-type="bibr" rid="bib55">Souza and Lerner, 2019</xref>; <xref ref-type="bibr" rid="bib56">Takami et al., 2002</xref>). High concentrations of curdlan (in the range of µg/mL) have been previously reported to decrease the overall differentiation of OCLs from Dectin-1-transfected RAW cells or from BM cells by upregulating <italic>Mafb</italic> and reducing <italic>Nfatc1</italic> expression (<xref ref-type="bibr" rid="bib65">Zhu et al., 2017</xref>). Our results extend these data by revealing that with much lower doses of curdlan (range of ng/mL), only i-OCL formation is inhibited whereas other OCLs are not affected, in line with the huge difference in Dectin-1 and Tlr2 expression by their respective progenitors. Interestingly, here we show that the yeast probiotic <italic>Sb</italic> significantly reduces bone loss in OVX mice. <italic>Sb</italic> has proven its beneficial probiotic effects in several gastrointestinal disorders. It favors regeneration of the integrity of the epithelial barrier in colitis and restores the gut microbiota after antibiotic treatment or diarrhea by increasing SCFA-producing bacteria such as <italic>Lachnospiraceae</italic>, <italic>Bacteroides</italic>, <italic>Ruminococcus,</italic> and <italic>Prevotellaceae</italic> (<xref ref-type="bibr" rid="bib41">Moré and Swidsinski, 2015</xref>; <xref ref-type="bibr" rid="bib57">Terciolo et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Yu et al., 2017</xref>). In line with this, our results demonstrate that <italic>Sb</italic> improves the gut barrier function in the context of OVX-induced osteoporosis. It also normalizes the concentration of SCFAs and lactate in OVX mice, which strongly suggests that <italic>Sb</italic> favors bacteria species producing these metabolites. Indeed previous studies reported that the diversity of intestinal microbiota is lower in OVX mice than in SHAM mice, and its composition is altered (<xref ref-type="bibr" rid="bib32">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Zaiss et al., 2019</xref>). LAB as well as SCFA-producing bacteria have a beneficial effect on bone (<xref ref-type="bibr" rid="bib64">Zaiss et al., 2019</xref>) which probably participates in the reduced bone loss observed in <italic>Sb</italic>-treated OVX mice. Moreover, gut dysbiosis and increased intestinal permeability reported in osteoporosis (<xref ref-type="bibr" rid="bib14">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Xu et al., 2020</xref>) induce activation of osteoclastogenic CD4<sup>+</sup> T cells over-producing Rank-L and Tnf-α (<xref ref-type="bibr" rid="bib7">D’Amelio et al., 2008</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2016</xref>). Thus, the reduction in BM Tnf-α-producing CD4<sup>+</sup> T cells observed after <italic>Sb</italic> treatment in OVX mice is likely due to its beneficial effect on the gut, as described for bacterial probiotics (<xref ref-type="bibr" rid="bib30">Li et al., 2016</xref>). As Tnf-α<sup>+</sup> CD4<sup>+</sup> T cells are major inducers of i-OCLs (<xref ref-type="bibr" rid="bib5">Ciucci et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Madel et al., 2019</xref>), this effect probably also participates in the decreased proportion of i-OCLs observed in <italic>Sb</italic>-treated OVX mice. In addition, in various models of gut disorders, <italic>Sb</italic> has been described to increase the production of anti-inflammatory cytokines such as IL-10 and IL-4 (<xref ref-type="bibr" rid="bib6">Czerucka and Rampal, 2019</xref>; <xref ref-type="bibr" rid="bib45">Pais et al., 2020</xref>) that are potent inhibitors of OCL formation (<xref ref-type="bibr" rid="bib11">Fujii et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Park-Min et al., 2009</xref>). Despite we did not detect significant difference in serum IL-10 concentration after Sb treatment in OVX mice (data not shown), we could not rule out local cytokine modification in the BM.</p><p>In addition to its systemic effects on inflammation and microbiota, <italic>Sb</italic> is also likely to directly affect i-OCL differentiation. The yeast cell wall components, ß-glucans, are well known to cross the gut barrier and translocate to the blood from where they can disseminate to organs (<xref ref-type="bibr" rid="bib21">Isnard et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Rice et al., 2005</xref>) and can directly modulate cells from the monocytic family (<xref ref-type="bibr" rid="bib18">Ibáñez et al., 2019a</xref>), which includes circulating OCL progenitors, through stimulation of CLRs. Consequently, in vivo they can possibly exert the same direct inhibitory effect on the differentiation of i-OCLs as observed in vitro. This is confirmed by our in vitro analysis showing a specific inhibition of i-OCL differentiation compared to t-OCLs by <italic>Sb</italic>, as well as low doses of agonists of Tlr2, Dectin-1, and Mincle, which is in line with the much higher expression of these receptors in BM-derived DCs than in BM MNs.</p><p>The inhibitory effect of Mincle stimulation observed here is contrasting with a recent publication reporting that sensing of necrotic cells through Mincle by OCL progenitors stimulates OCL formation (<xref ref-type="bibr" rid="bib2">Andreev et al., 2020</xref>). <italic>Clec4e</italic> KO mice have increased bone mass (<xref ref-type="bibr" rid="bib2">Andreev et al., 2020</xref>), a result confirmed by our study. However, we also observed a similar or even higher OCL formation from progenitors from <italic>Clec4e</italic> KO compared to control mice. Mincle is not expressed by osteoblasts (<xref ref-type="bibr" rid="bib2">Andreev et al., 2020</xref>), but the increased bone mass observed in <italic>Clec4e</italic> KO mice could be related to indirect effects of Mincle on osteoblasts and OCLs through myeloid cells that are well-known regulators of bone cell differentiation and activity (<xref ref-type="bibr" rid="bib61">Yahara et al., 2021</xref>). Moreover, Mincle KO mice display reduced CD4<sup>+</sup>IL-17<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib37">Martínez-López et al., 2019</xref>), which may also contribute to a reduced OCL differentiation and increased bone mass. It is therefore likely that depending on whether Mincle is stimulated by exogenous microbial signals (as in our study) or endogenous necrotic signals (as in Andreev’s study), this receptor has divergent effects on osteoclastogenesis. These observations revealed the complex effects of Mincle on osteoclastogenesis, as already reported for other monocytic cells (<xref ref-type="bibr" rid="bib47">Patin et al., 2017</xref>).</p><p>The kinase Syk plays a major role in Dectin-1 and Mincle signaling pathways, and indeed, Syk is rapidly phosphorylated upon curdlan stimulation in BM-DCs. On the other hand, Syk is required for efficient OCL differentiation (<xref ref-type="bibr" rid="bib66">Zou et al., 2007</xref>), including from DCs as shown here. However, in DCs stimulated with curdlan in osteoclastogenic medium, the expression of <italic>Syk</italic> decreases with time together with <italic>Nfatc1</italic>, a master gene of OCL differentiation, and <italic>Ctsk</italic>, a main marker of OCLs required for their activity, which participates in reducing i-OCL formation. These results are in agreement with the literature showing in the same conditions a degradation of Syk after treatment with high doses of curdlan (<xref ref-type="bibr" rid="bib62">Yamasaki et al., 2014</xref>). In DCs, the interaction between Tlr2 and Dectin-1 is involved in the stimulation of NF-κB and in the production of inflammatory cytokines such as Tnf-α and IL-12 (<xref ref-type="bibr" rid="bib12">Gantner et al., 2003</xref>; <xref ref-type="bibr" rid="bib51">Sancho and Reis e Sousa, 2012</xref>). This strongly induces DC activation and therefore potent phagocytic and anti-microbial responses (<xref ref-type="bibr" rid="bib12">Gantner et al., 2003</xref>; <xref ref-type="bibr" rid="bib51">Sancho and Reis e Sousa, 2012</xref>). Accordingly, we show that treatment with curdlan or with <italic>Sb</italic>-CM induces DC maturation while it decreases the proportion of Rank<sup>+</sup> cells expressing Csf1r and FcgrII/III, all of which are required for OCL formation. Thus, stimulation of DCs with the PRR agonists has a dual effect, i.e., increasing their maturation and simultaneously reducing their ability to give rise to i-OCLs.</p><p>In conclusion, we here demonstrated that i-OCLs differ from t-OCLs in the control of their differentiation and in their capacity to sense their environment and in particular to respond to stimuli through CLR and TLR activation. Based on these properties, we demonstrated that the probiotic yeast <italic>Sb</italic> has a beneficial effect on bone loss in osteoporotic mice by restoring gut barrier integrity and reducing osteoclastogenic CD4<sup>+</sup> T cells thereby reducing indirectly i-OCLs. Moreover, it also directly targets i-OCL progenitors to interfere with their differentiation.</p><p>These insights open new interesting perspectives for the treatment of pathological bone resorption by demonstrating that the Ig-like receptor costimulatory pathway and the associated PRR pathway, rather than the Rank pathway, could represent efficient therapeutic targets to specifically impact on inflammatory osteoclastogenesis while maintaining physiological OCL resorption. The dose of <italic>Sb</italic> used in mice is much higher than that recommended for humans. However, this is also true in studies evaluating probiotic lactobacillus strains in osteoporosis that have shown protective effects at much lower doses in humans than in mice (<xref ref-type="bibr" rid="bib3">Britton et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Nilsson et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Jansson et al., 2019</xref>). Therefore, <italic>Sb</italic> administration in osteoporotic patients would represent a feasible possibility. These novel insights and regulatory mechanisms mediated by yeast probiotics could provide new therapeutic options to overcome the global inhibition of OCLs and the resulting impaired bone quality associated with current anti-resorptive therapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>CD11cΔSyk</italic> and <italic>CD11c-Cre</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib20">Iborra et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">B6.Cg-<italic>Clec4e<sup>t</sup></italic><sup>m1.1Cfg</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Wells et al., 2008</xref></td><td align="left" valign="bottom"><italic>Clec4e<sup>−/−</sup></italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>yeast</italic>)</td><td align="left" valign="bottom"><italic>Saccharomyces boulardii</italic> (Ultralevure)</td><td align="left" valign="bottom">Biocodex</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD11b</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">clone M1/70</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD11c</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">clone HL3</td><td align="left" valign="bottom">1:200, for cell isolation</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD11c</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">clone N418</td><td align="left" valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Dectin-1</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">clone bg1fpj</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Dectin-1</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">clone bg1fpj</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Dectin-2</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">clone 17611</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TLR2</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">clone 6C2</td><td align="left" valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mincle</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">clone 6G5</td><td align="left" valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mαr IgG2b secondary</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">ref SA5-10184</td><td align="left" valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MHC-II/Iab</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">clone AF6-120.1</td><td align="left" valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD80</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">clone 16–10 A1</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD86</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">clone GL1</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD115</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">clone AFS98</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RANK/CD265</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">clone R12-31</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TNF</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">clone MP6-XT22</td><td align="left" valign="bottom">1:400</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Cx3cr1</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">clone 2A9-1</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD16/32</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">clone 93</td><td align="left" valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD4</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">clone RM4-5</td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-Syk (Tyr348)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">clone moch1ct</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Osterix</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab22552</td><td align="left" valign="bottom">dilution 1:800</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-sclerostin</td><td align="left" valign="bottom">R&amp;D System</td><td align="left" valign="bottom">AF1589</td><td align="left" valign="bottom">dilution 1:200</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>36B4</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCAGGCTTTGGGCATCA and CTTTATCAGCTGCACATCACTCAGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Syk</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AACGTGCTTCTGGTCACACA and AGAACGCTTCCCACATCAGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ctsk</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAGCAGAGGTGTGTACTATG and GCGTTGTTCTTATTCCGAGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Nfatc1</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGAGGCTGGTCTTCCGAGTT and CGCTGGGAACACTCGATAGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">si<italic>Tlr2</italic></td><td align="left" valign="bottom">Horizon Discovery LTD</td><td align="left" valign="bottom">L-062838–02- 0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Curdlan</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C7821</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Zymosan</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Z4250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GlcC<sub>14</sub>C<sub>18</sub></td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">tlrl-gcc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FITC dextran</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">FD4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">H33342</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">B2261</td><td align="left" valign="bottom">5 µg/mL</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RatLaps (CTX-I) EIA</td><td align="left" valign="bottom">Immunodiagnostic Systems Limited</td><td align="left" valign="bottom">NC9787201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Annexin V Apoptosis detection kit</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">556547</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Acid Phosphatase Leucocyte kit</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">387 A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">rmRANKL</td><td align="left" valign="bottom">R&amp;D System</td><td align="left" valign="bottom">462-TEC</td><td align="left" valign="bottom">30 ng/mL</td></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">rmM-CSF</td><td align="left" valign="bottom">R&amp;D System</td><td align="left" valign="bottom">416 ML</td><td align="left" valign="bottom">25 ng/mL</td></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">rmIL4</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">214–14</td><td align="left" valign="bottom">10 ng/mL</td></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">rmGM-CSF</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">315–03</td><td align="left" valign="bottom">10 ng/mL</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ software version 1.53</td><td align="left" valign="bottom">NIH, Bethesda, MD</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo 10.8.1</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NRecon software</td><td align="left" valign="bottom">Bruker µCT, Belgium</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Graph Pad Prism 9.4 software</td><td align="left" valign="bottom">Graph Pad Prism</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice and ovariectomy-induced osteoporosis</title><p>C57BL/6 mice were purchased from Charles River Laboratory at 4 weeks of age and housed in the Animal Facility of the University Côte d’Azur. Animals were maintained under a 12-hr light/dark cycle, and food and tap water were provided ad libitum. Female 6-week-old C57BL/6 mice were randomly divided into two groups for subsequent bilateral ovariectomy or SHAM surgery and were closely monitored until complete healing. Starting from 2 weeks after surgery, mice received by gavage <italic>Sb</italic> (Biocodex, Gentilly, France) 3 g/kg of body weight, 3 times per week until the end of the experiment. Six weeks after surgery, mice were sacrificed. <italic>CD11cΔ</italic>Syk <italic>mice and CD11c-Cre</italic> littermates (<xref ref-type="bibr" rid="bib20">Iborra et al., 2012</xref>) as well as <italic>Clec4e</italic><sup>+/+</sup> and <italic>Clec4e</italic><sup>−/−</sup> (B6.Cg-<italic>Clec4e</italic><sup>tm1.1Cfg</sup>) (<xref ref-type="bibr" rid="bib58">Wells et al., 2008</xref>) female mice were bred in Centro Nacional de Investigaciones Cardiovasculares in SPF conditions. All experiments were approved by the French Ministry of Health, Higher Education and Research (autorization number 8389–2016121216457153 v3) and conducted in accordance with the Institutional Ethics Committee on Laboratory Animals (CIEPAL-Azur, Nice Sophia-Antipolis, France).</p></sec><sec id="s4-2"><title>Primary cell culture and osteoclast differentiation</title><p>i-OCLs and t-OCLs were differentiated in vitro as described previously (<xref ref-type="bibr" rid="bib13">Halper et al., 2021</xref>; <xref ref-type="bibr" rid="bib17">Ibáñez et al., 2016</xref>) from 6-week-old C57BL/6 mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Briefly, CD11c<sup>+</sup> BM-derived DCs cells were obtained by culturing 5×10<sup>5</sup> BM cells/well in 24-well plates in RPMI medium (ThermoFisher Scientific) supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin (ThermoFisher Scientific), 50 µM 2-mercaptoethanol (ThermoFisher Scientific), 10 ng/mL Gm-csf, and 10 ng/mL IL-4 (both PeproTech). The differentiation of t-OCLs and i-OCLs took 4–5 days and 5–6 days, respectively. CD11c<sup>+</sup> DCs were isolated using biotinylated anti-CD11c (1:200; clone HL3; BD Biosciences) and anti-biotin microbeads (Miltenyi Biotec). iOCLs were differentiated by seeding a total of 2×10<sup>4</sup> CD11c<sup>+</sup> DCs/well on 24-well plates in MEM-alpha (ThermoFisher Scientific) including 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM 2-mercaptoethanol, 25 ng/mL M-csf, and 30 ng/mL Rank-L (both R&amp;D) (OCL differentiation medium). For t-OCL culture, 2×10<sup>5</sup> CD11b<sup>+</sup> monocytic BM cells that were isolated by biotinylated anti-CD11b (1:100; clone M1/70; ThermoFisher Scientific) and anti-biotin microbeads (Miltenyi Biotec) were seeded per well on 24-well plates in OCL differentiation medium as described above. For OCL differentiation from OVX and SHAM control mice, 5×10<sup>5</sup> BM cells were cultured per well in 24-well plates in OCL differentiation medium as indicated above. When indicated, differentiation was performed in the presence of indicated concentrations of curdlan, zymosan, or GlcC<sub>14</sub>C<sub>18</sub>. Medium conditioned by <italic>Sb</italic> CNCM I-745 (<italic>Sb</italic>-CM) was prepared by culture of the yeast in MEM-alpha overnight. The medium was collected and filtered through a sterile 22-µm filter, complemented with serum and antibiotics as described above and used as CM at indicated dilutions. All agonists and <italic>Sb</italic>-CM were added at day 0 (start of culture) and day 3 when the medium was changed. OCL differentiation was evaluated at the end of the differentiation after TRAcP staining according to manufacturer’s instructions (Sigma-Aldrich). Mature OCLs were enumerated under a light microscope as multinucleated (≥three nuclei/cell) TRAcP<sup>+</sup> cells. OCL activity was evaluated by seeding OCL progenitors on plates coated with resorbable matrix (Osteoassay) in OCL differentiation medium. All agonists and <italic>Sb</italic>-CM were added at day 3 when the medium was changed and OCLs started to fuse. Resorbed areas were quantified (ImageJ software version 1.53, NIH, Bethesda, MD) after removing of the cells with water and staining of the mineralized matrix with alizarin red.</p></sec><sec id="s4-3"><title>RNA-sequencing</title><p>RNAseq analysis was performed on mature multinucleated OCLs. After differentiation in vitro, t-OCLs and i-OCLs (five biological replicates, each derived from one mouse) were detached with Accutase, labeled with 5 µg/mL H33342, and sorted on their multinucleation as previously described (<xref ref-type="bibr" rid="bib34">Madel et al., 2018</xref>; c.f. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref> for the gating strategy). Total RNA (100 ng) was extracted from sorted OCLs (RNeasy kit, Qiagen), and directional libraries were prepared (Truseq stranded total RNA library kit, Illumina). Libraries were pooled and sequenced paired-ended for 2×75 cycles (Nextseq500 sequencer, Illumina). 30–40 million fragments were generated per sample, and quality controls were performed. Data were analyzed by two approaches as described previously (<xref ref-type="bibr" rid="bib36">Madel et al., 2020</xref>). Both gave equivalent results. For the first one, reads were ‘quasi’ mapped on the reference mouse transcriptome (Gencode vM15) and quantified (SALMON software, mapping mode and standard settings) (<xref ref-type="bibr" rid="bib48">Patro et al., 2017</xref>). Transcript count estimates and confidence intervals were computed using 1.000 bootstraps to assess technical variance. Transcript counts were aggregated for each gene for computing gene expression levels. Gene expression in biological replicates (n=5) was then compared between t-OCLs and i-OCLs using Phantassus and the limma R package (<ext-link ext-link-type="uri" xlink:href="https://ctlab.itmo.ru/phantasus">https://ctlab.itmo.ru/phantasus</ext-link>) (<xref ref-type="bibr" rid="bib8">Daria Zenkova, 2018</xref>). For the second approach, raw FASTQ reads were trimmed with Trimmomatic and aligned to the reference mouse transcriptome (Gencode mm10) with STAR (<xref ref-type="bibr" rid="bib9">Dobin et al., 2013</xref>) on the National Institutes of Health high-performance computing Biowulf cluster. Gene-assignment and estimated read counts were assessed using HTseq (<xref ref-type="bibr" rid="bib1">Anders et al., 2015</xref>). Gene expression was compared between t-OCLs and i-OCLs using DESeq2 (<xref ref-type="bibr" rid="bib33">Love et al., 2014</xref>) with the Wald test (FDR &lt;0.01).</p></sec><sec id="s4-4"><title>miRNA profiling and validation by RT-qPCR</title><p>Total RNA from sorted OCLs was extracted using the miRNeasy Micro Kit (QIAGEN), and the procedure automatized using the QIAcube (QIAGEN). The miRNA expression profiles were analyzed on paired samples using the TaqMan Array rodent MicroRNA Card Set v3.0 (TLDA, Applied Biosystems) after pre-amplification steps, according to manufacturer’s instructions. Relative expression and statistical analysis were calculated using the ExpressionSuite software (Applied Biosciences), which included the student’s t-test for sample group comparisons and built Volcano Plot comparing the size of the fold change (biological significance) to the statistical significance (p-value). Dysregulated miRNAs were examined with MirWalk (<xref ref-type="bibr" rid="bib10">Dweep and Gretz, 2015</xref>), a miRNA database aiming to identify predicted and validated target genes and related pathways. This software provides information on miRNA-target interactions, not only on 3′-UTR, but also on the other regions of all known genes and simultaneously interrogates several algorithms (TargetScan, Miranda, RNA22, and miRWalk). We used a high predictive score with at least three of the four queried algorithms predicting miRNA target genes. Comparison of the expression patterns of 750 miRNAs in i-OCLs and t-OCLs was performed using Ct values &lt;35, difference of at least twofold with a p-value &lt;0.05.</p><p>Mature miRNAs of interest were specifically converted into cDNA using TaqMan microRNA reverse transcription kit according to the manufacturer’s protocol (Applied Biosystems). RT-specific primers 5× (ThermoFisher) were multiplexed in a primer pool containing 1% of each diluted in an adequate volume of Tris-EDTA 1× . Pre-amplification step was performed using FAM-labeled specific PCR primers 20× and TaqMan PreAmp Master Mix kit (Applied Biosystems) for 12 cycles. Alternatively, these preliminary steps were performed using Megaplex RT and PreAmp Primers, Rodent pool A (Applied Biosystems) that include specific primers for miRNAs of interest. was performed on diluted pre-amp products using the specific TaqMan PCR primers and TaqMan Universal Master Mix II with no uracile N-glycosylase and run on Viia7 system (Applied Biosystems) in 96-well PCR plates for 40 cycles. Relative miRNA expression was normalized on sno202 expression in murine cells with the 2<sup>−ΔCT</sup> method.</p></sec><sec id="s4-5"><title>Bone structure analyses</title><p>Long bones of OVX and SHAM-operated mice were fixed in 4% paraformaldehyde. Bone microarchitecture analysis using high-resolution µCT was performed at the pre-clinical platform ECELLFRANCE (IRMB, Montpellier, France). Cortical and trabecular femora were imaged using high-resolution µCT with a fixed isotropic voxel size of 9 µm with X-ray energy of 50 kV, current of 500 mA, 0.5 mm aluminum filter, and 210 ms exposure time. Quantification of bone parameters was performed on the trabecular region of the proximal part of each femur (1.72 mm long) and on the cortical region (0.43 mm long region centered at the femoral midshaft) on CT Analyzer software (Bruker microCT, Belgium). For visual representation, 3D reconstructions were generated using NRecon software (Bruker µCT, Belgium).</p></sec><sec id="s4-6"><title>FITC-dextran permeability assay</title><p>At 1 hr before sacrifice, mice received oral gavage of 3–5 kDa FITC–dextran (Sigma-Aldrich) (60 mg/100 g body weight). FITC-dextran concentration in serum was measured by fluorometry in a fluorimeter (Xenius, SAFAS, Monaco) at 488/525 nm. Standard curve was prepared using dilutions of FITC-dextran in PBS with 20% fetal calf serum.</p></sec><sec id="s4-7"><title>TRAcP staining and immunohistochemistry</title><p>Tibias were fixed in 4% paraformaldehyde and decalcified for 72 hr in 4.13% EDTA, 0.2% paraformaldehyde pH 7.4, at 50°C in KOS microwave tissue processor (Milestone, Michigan, USA). They were then dehydrated and embedded in paraffin. TRAcP staining was performed as described (<xref ref-type="bibr" rid="bib28">Lézot et al., 2015</xref>) with Mayer hematoxylin counterstaining on 3-μm thick sections to identify OCLs and three images of four to five biological replicates were analyzed. Immunostaining of osteoblasts and osteocytes was performed with rabbit polyclonal anti-Osterix antibody (ab22552, dilution 1/800; Abcam, Cambridge, UK) and rabbit polyclonal anti-sclerostin antibody (AF1589, dilution1:200; R&amp;D System, Abingdon, UK), respectively, with Gill2 hematoxylin counterstaining. For enumeration of osteoblasts and osteocytes, one image of four to five biological replicates was analyzed. Analyses were performed on the entire trabecular area axcluding the cortical area. Stained sections were automatically numerized (nanozoomer, Hamamatsu photonics) before observation (NDP view virtual microscope, Hamamatsu) and quantification (ImageJ software version 1.53, NIH, Bethesda, MD).</p></sec><sec id="s4-8"><title>Dosage of biochemical parameters</title><p>Concentration of lactate, propionate, and butyrate in the serum was determined by ion chromatography analysis after depletion of proteins and lipids with acetonitrile (Sigma-Aldrich). Samples were loaded on a Dionex ICS-5000 Plus system automatic device (ThermoScientific), and elution was performed according to the manufacturer’s protocol. Chromatograms were aligned to standard solutions of each compound individually. Compound concentrations were determined using Chromeleon software (Thermo Scientific) by measuring surface area under the curve of the peaks and were compared to the corresponding ion standard profiles.</p><p>Serum crosslaps (CTX) were evaluated by enzyme-linked immunosorbent assay according to the manufacturer’s protocol (RatLaps (CTX-I) EIA, Immunodiagnostic Systems Limited).</p></sec><sec id="s4-9"><title>Flow cytometry analysis</title><p>CD11b<sup>+</sup> monocytic BM cells and BM-derived CD11c<sup>+</sup> DCs cells were analyzed for their expression of Dectin-1 (1:100; clone bg1fpj; ThermoFisher Scientific), Dectin-2 (1:100, clone 17611; R&amp;D Systems), Tlr2 (1:200; clone 6C2; BD Biosciences), and Mincle (1:50, clone 6G5, Invivogen).</p><p>For analysis of BM-derived DC maturation, BM-DCs were treated or not with curdlan or <italic>Sb</italic>-CM at the indicated dose for 24 hr in OCL differentiation medium (containing 25 ng/mL M-csf and 30 ng/mL Rank-L). They were then labeled with anti-CD11c (1:200; Clone N418, eBioscience), MHC-II/IAb (1:200; Clone AF6-120.1, BD Bioscience), CD80 (1:100; Clone 16–10 A1, eBioscience), CD86 (1:100; Clone GL1, BD Bioscience), CD115 (1:100; Clone AFS98, eBioscience), and Rank/CD265 (1:100; clone R12-31, eBioscience). Cells were analyzed by flow cytometry (BD FACSCanto-II, BD Bioscience).</p><p>To investigate the Syk phosphorylation after curdlan stimulation, BM-derived DCs were stimulated for 15 min in OCL differentiation medium with the indicated doses of curdlan and subsequently fixed with 2% PFA (Transcription Factor Fixation/Permeabilization kit, eBioscience) over night at 4°C. Surface staining was then performed with anti-MHC-II/IAb (1:100;Clone AF6-120.1, BD Bioscience) and CD11c (1:200; Clone N418, eBioscience) antibodies before the cells were permeabilized with 1× Saponine (1 g/100 mL) for 15 min and stained with Phospho-Syk (Tyr348, clone moch1ct, eBioscience) for 45 min. Cells were washed and acquired on a BD FACSCanto II.</p><p>For FACS analysis on OCLs, mature OCLs were detached using Accutase (ThermoFisher Scientific), labeled with 5 µg/mL H33342 and with anti-Dectin-1, Dectin-2, Tlr2, and Mincle antibodies and analyzed after doublet exclusion as multinucleated cells with three or more nuclei as previously described (<xref ref-type="bibr" rid="bib34">Madel et al., 2018</xref>) for their expression of these markers (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref> for the gating strategy). Cells were analyzed by flow cytometry (BD FACSCanto-II, BD Bioscience).</p><p>For intracellular cytokine analysis, T cells isolated from the BM of SHAM and OVX mice were stimulated with phorbol myristate acetate (PMA), ionomycin, and brefeldin A, labeled with anti-CD4 antibody (1:1000; clone RM4-5; BD Biosciences) and fixed with 4% formaldehyde overnight as described (<xref ref-type="bibr" rid="bib5">Ciucci et al., 2015</xref>). Cells were subsequently stained with anti-Tnf-α antibody (1:400; clone MP6-XT22; ThermoFisher Scientific) in 1× Saponine (1 g/100 mL). Data were acquired using a FACSCanto-II (BD Biosciences). All FACS data were analyzed with FlowJo 10.8.1.</p></sec><sec id="s4-10"><title>In vitro mineralization assay</title><p>Osteoblastic differentiation of BM-MSC cells from C57Bl/6 mice was performed for 3 weeks in MEM-alpha medium with 10% FBS, 1% penicillin-streptomycin, 50 µM b-mercaptoethanol supplemented with 170 µM L-ascorbic acid, 10 mM β-glycerophosphate, and 0.1 µM dexamethasone (Merck). This differentiation medium (with adjusted concentration of inductors) was supplemented with the indicated % of <italic>Sb</italic>-CM. Medium was changed every 4 days. At day 21, cultures were fixed with 4% PFA and stained with 2% Alizarin red S (Merck). For the quantification, the Alizarin staining was dissolved in acetic acid (10%), heated 10 min at 85°C, centrifuged, and buffered with ammonium hydroxide. Absorbance at 405 nm was measured (Xenius SAFAS, Monaco).</p></sec><sec id="s4-11"><title>Blocking of Dectin-1, TLR2, and Mincle</title><p>For inhibition with siRNA, BM-derived DCs were transfected with ON-TARGET SMART pool of four siRNA to mouse <italic>Tlr2</italic> (50 nM, Dharmacon, Horizon Discovery, USA) using lipofectamine RNAiMAX (Invitrogen) and were further differentiated into OCLs for 5–6 days either in OCL differentiation medium in the presence of the indicated concentration of agonists, or in <italic>Sb</italic>-CM as described above.</p><p>For inhibition with blocking antibodies, BM-derived DCs were cultured either in OCL differentiation medium containing the indicated concentration of agonists, or in <italic>Sb</italic>-CM. Anti-Dectin-1 (clone bg1fpj; ThermoFisher Scientific), anti-Mincle (clone 6G5, Invivogen), or control isotype antibodies were added at the indicated concentration at the beginning of the differentiation. Medium was changed at day 3.</p><p>For both approaches, OCLs differentiation was evaluated after TRAcP staining, and mature OCLs were enumerated under a light microscope as multinucleated TRAcP<sup>+</sup> cells.</p></sec><sec id="s4-12"><title>RT-qPCR</title><p>BM-derived DCs were stimulated for 72 hr with the indicated doses of curdlan. Total RNA was extracted with Trizol according to the manufacturer protocol. RNAs were reverse transcribed (Superscript II, Life Technologies), and RT-PCR was performed using SYBR green and the primers indicated below. Results were normalized to the 36B4 gene with the 2<sup>−ΔCt</sup> method. <italic>Syk</italic>: <named-content content-type="sequence">AACGTGCTTCTGGTCACACA</named-content> and <named-content content-type="sequence">AGAACGCTTCCCACATCAGG</named-content>; <italic>Ctsk</italic>: CAGCAGAGGTGTGTACTATG and GCGTTGTTCTTATTCCGAGC; <italic>Nfatc1</italic>: TGAGGCTGGTCTTCCGAGTT and CGCTGGGAACACTCGATAGG; <italic>Rplp0</italic>: TCCAGGCTTTGGGCATCA and CTTTATCAGCTGCACATCACTCAGA.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>Data were analyzed and statistics prepared using Graph Pad Prism 9.2 software. Analyses were done using two-tailed unpaired t-test when comparing two groups and ANOVA with multiple comparison test when comparison of more than two groups. Statistical significance was considered at p&lt;0.05, and experimental values are presented as mean ± SD. Biological replicates were obtained from different mice.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>received a research grant from Biocodex. Biocodex had no role in the design of the study, in the analysis and interpretation of the data and in the preparation of the manuscript</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Supervision</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Funding acquisition</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Writing – review and editing, Writing – original draft</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con13"><p>Writing – review and editing, Validation</p></fn><fn fn-type="con" id="con14"><p>Writing – review and editing, Investigation</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Formal analysis, Funding acquisition, Supervision, Writing – review and editing, Provided and participated in experiments on CD11c-Syk mutant mice</p></fn><fn fn-type="con" id="con17"><p>Funding acquisition, Writing – review and editing, Provided and participated in experiments on CD11c-Syk mutant mice</p></fn><fn fn-type="con" id="con18"><p>Formal analysis, Funding acquisition, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experiments were approved by the french ministry of health, higher education and research (autorization number 8389-2016121216457153v3) and conducted in accordance with the Institutional Ethics Committee on Laboratory Animals (CIEPAL-Azur, Nice Sophia-Antipolis, France).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-82037-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>RNAseq data have been deposited in ENA (European Nucleotide Archive) accession number PRJEB42043.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Madel</surname><given-names>MB</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Targeting inflammatory osteoclasts with probiotic yeast S. boulardii reduces bone loss in osteoporosis</data-title><source>ENA</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB42043">PRJEB42043</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to acknowledge the Genomic Facility of the UFR Simone Veil, Université Versailles-Saint-Quentin (France) for the RNA sequencing, the IRCAN animal core facility that is supported by “la Région Provence Alpes-Côte d’Azur” (Nice, France) as well as the Montpellier preclinical platform of ECELLFRANCE for µCT analysis (IRMB, Montpellier, France). They also thank the Laboratory of Biochemistry-Hormonology (CHU, Nice, France) for CTX dosage and M Salah and D Carro (LP2M, Nice France) for their technical contribution. This work utilized the computational resources of the NIH-HPC-Biowulf cluster (<ext-link ext-link-type="uri" xlink:href="http://hpc.nih.gov">http://hpc.nih.gov</ext-link>).</p><p>The work was supported by the Agence Nationale de la Recherche (ANR-16-CE14-0030) as well as by the French government, managed by the ANR as part of the Investissement d’Avenir UCA<sup>JEDI</sup> project (ANR-15-IDEX-01) and Biocodex (Gentilly, France). M-B M was supported by the Fondation pour la Recherche Médicale (FRM, ECO20160736019), and by awards from the Fondation Arthritis, the Société Française de Biologie des Tissus Minéralisés (SFBTM), the European Calcified Tissue Society (ECTS) and the American Society of Bone and Mineral Research (ASBMR). J.H. was supported by an award from ECTS, an award from SFBTM, and a fellowship from the Société Française de Rhumatologie (SFR). T.C. was supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreev</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Weidner</surname><given-names>D</given-names></name><name><surname>Kachler</surname><given-names>K</given-names></name><name><surname>Faas</surname><given-names>M</given-names></name><name><surname>Grüneboom</surname><given-names>A</given-names></name><name><surname>Schlötzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Muñoz</surname><given-names>LE</given-names></name><name><surname>Steffen</surname><given-names>U</given-names></name><name><surname>Grötsch</surname><given-names>B</given-names></name><name><surname>Killy</surname><given-names>B</given-names></name><name><surname>Krönke</surname><given-names>G</given-names></name><name><surname>Luebke</surname><given-names>AM</given-names></name><name><surname>Niemeier</surname><given-names>A</given-names></name><name><surname>Wehrhan</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Bozec</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>4811</fpage><lpage>4830</lpage><pub-id pub-id-type="doi">10.1172/JCI134214</pub-id><pub-id pub-id-type="pmid">32773408</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britton</surname><given-names>RA</given-names></name><name><surname>Irwin</surname><given-names>R</given-names></name><name><surname>Quach</surname><given-names>D</given-names></name><name><surname>Schaefer</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Parameswaran</surname><given-names>N</given-names></name><name><surname>McCabe</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Probiotic L. reuteri treatment prevents BONE LOSS in a menopausal ovariectomized mouse model: probiotics suppress estrogen deficiency-induced bone loss</article-title><source>Journal of Cellular Physiology</source><volume>229</volume><fpage>1822</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1002/jcp.24636</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cenci</surname><given-names>S</given-names></name><name><surname>Weitzmann</surname><given-names>MN</given-names></name><name><surname>Roggia</surname><given-names>C</given-names></name><name><surname>Namba</surname><given-names>N</given-names></name><name><surname>Novack</surname><given-names>D</given-names></name><name><surname>Woodring</surname><given-names>J</given-names></name><name><surname>Pacifici</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha</article-title><source>The Journal of Clinical Investigation</source><volume>106</volume><fpage>1229</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1172/JCI11066</pub-id><pub-id pub-id-type="pmid">11086024</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciucci</surname><given-names>T</given-names></name><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Boucoiran</surname><given-names>A</given-names></name><name><surname>Birgy-Barelli</surname><given-names>E</given-names></name><name><surname>Pène</surname><given-names>J</given-names></name><name><surname>Abou-Ezzi</surname><given-names>G</given-names></name><name><surname>Arab</surname><given-names>N</given-names></name><name><surname>Rouleau</surname><given-names>M</given-names></name><name><surname>Hébuterne</surname><given-names>X</given-names></name><name><surname>Yssel</surname><given-names>H</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bone marrow th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD</article-title><source>Gut</source><volume>64</volume><fpage>1072</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-306947</pub-id><pub-id pub-id-type="pmid">25298539</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czerucka</surname><given-names>D</given-names></name><name><surname>Rampal</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Diversity of <italic>saccharomyces boulardii</italic> CNCM I-745 mechanisms of action against intestinal infections</article-title><source>World Journal of Gastroenterology</source><volume>25</volume><fpage>2188</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i18.2188</pub-id><pub-id pub-id-type="pmid">31143070</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Amelio</surname><given-names>P</given-names></name><name><surname>Grimaldi</surname><given-names>A</given-names></name><name><surname>Di Bella</surname><given-names>S</given-names></name><name><surname>Brianza</surname><given-names>SZM</given-names></name><name><surname>Cristofaro</surname><given-names>MA</given-names></name><name><surname>Tamone</surname><given-names>C</given-names></name><name><surname>Giribaldi</surname><given-names>G</given-names></name><name><surname>Ulliers</surname><given-names>D</given-names></name><name><surname>Pescarmona</surname><given-names>GP</given-names></name><name><surname>Isaia</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis</article-title><source>Bone</source><volume>43</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2008.02.017</pub-id><pub-id pub-id-type="pmid">18407820</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daria Zenkova</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phantasus</article-title><source>Bioconductor</source><volume>3.16</volume><elocation-id>B9</elocation-id><pub-id pub-id-type="doi">10.18129/B9.BIOC.PHANTASUS</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dweep</surname><given-names>H</given-names></name><name><surname>Gretz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MiRWalk2.0: a comprehensive atlas of microrna-target interactions</article-title><source>Nature Methods</source><volume>12</volume><elocation-id>697</elocation-id><pub-id pub-id-type="doi">10.1038/nmeth.3485</pub-id><pub-id pub-id-type="pmid">26226356</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Kitaura</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Hakami</surname><given-names>ZW</given-names></name><name><surname>Takano-Yamamoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo</article-title><source>Bone</source><volume>51</volume><fpage>771</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2012.06.024</pub-id><pub-id pub-id-type="pmid">22776139</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantner</surname><given-names>BN</given-names></name><name><surname>Simmons</surname><given-names>RM</given-names></name><name><surname>Canavera</surname><given-names>SJ</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Underhill</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2</article-title><source>The Journal of Experimental Medicine</source><volume>197</volume><fpage>1107</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1084/jem.20021787</pub-id><pub-id pub-id-type="pmid">12719479</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halper</surname><given-names>J</given-names></name><name><surname>Madel</surname><given-names>MB</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differentiation and phenotyping of murine osteoclasts from bone marrow progenitors, monocytes, and dendritic cells</article-title><source>Methods in Molecular Biology</source><volume>2308</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1425-9_2</pub-id><pub-id pub-id-type="pmid">34057711</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Si</surname><given-names>F</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gut microbiota and metabolite alterations associated with reduced bone mineral density or bone metabolic indexes in postmenopausal osteoporosis</article-title><source>Aging</source><volume>12</volume><fpage>8583</fpage><lpage>8604</lpage><pub-id pub-id-type="doi">10.18632/aging.103168</pub-id><pub-id pub-id-type="pmid">32392181</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>RB</given-names></name><name><surname>Krönke</surname><given-names>G</given-names></name><name><surname>Zwerina</surname><given-names>J</given-names></name><name><surname>Redlich</surname><given-names>K</given-names></name><name><surname>Hueber</surname><given-names>AJ</given-names></name><name><surname>Gelse</surname><given-names>H</given-names></name><name><surname>Neumann</surname><given-names>E</given-names></name><name><surname>Müller-Ladner</surname><given-names>U</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis</article-title><source>Arthritis and Rheumatism</source><volume>58</volume><fpage>3041</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1002/art.23943</pub-id><pub-id pub-id-type="pmid">18821671</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>MB</given-names></name><name><surname>Nakamura</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A comprehensive review of immunoreceptor regulation of osteoclasts</article-title><source>Clinical Reviews in Allergy &amp; Immunology</source><volume>51</volume><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s12016-015-8521-8</pub-id><pub-id pub-id-type="pmid">26573914</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Abou-Ezzi</surname><given-names>G</given-names></name><name><surname>Ciucci</surname><given-names>T</given-names></name><name><surname>Amiot</surname><given-names>V</given-names></name><name><surname>Belaïd</surname><given-names>N</given-names></name><name><surname>Obino</surname><given-names>D</given-names></name><name><surname>Mansour</surname><given-names>A</given-names></name><name><surname>Rouleau</surname><given-names>M</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory osteoclasts prime TNFα-producing CD4(+) T cells and express CX3 CR1</article-title><source>Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research</source><volume>31</volume><fpage>1899</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2868</pub-id><pub-id pub-id-type="pmid">27161765</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Pontier-Bres</surname><given-names>R</given-names></name><name><surname>Larbret</surname><given-names>F</given-names></name><name><surname>Rekima</surname><given-names>A</given-names></name><name><surname>Verhasselt</surname><given-names>V</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name><name><surname>Czerucka</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Saccharomyces boulardii strain CNCM I-745 modifies the mononuclear phagocytes response in the small intestine of mice following salmonella typhimurium infection</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>643</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00643</pub-id><pub-id pub-id-type="pmid">31001263</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Rouleau</surname><given-names>M</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Gut microbiome and bone</article-title><source>Joint Bone Spine</source><volume>86</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2018.02.008</pub-id><pub-id pub-id-type="pmid">29654948</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iborra</surname><given-names>S</given-names></name><name><surname>Izquierdo</surname><given-names>HM</given-names></name><name><surname>Martínez-López</surname><given-names>M</given-names></name><name><surname>Blanco-Menéndez</surname><given-names>N</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name><name><surname>Sancho</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>1628</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1172/JCI60660</pub-id><pub-id pub-id-type="pmid">22505455</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isnard</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Bu</surname><given-names>S</given-names></name><name><surname>Fombuena</surname><given-names>B</given-names></name><name><surname>Royston</surname><given-names>L</given-names></name><name><surname>Routy</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gut leakage of fungal-related products: turning up the heat for HIV infection</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>656414</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.656414</pub-id><pub-id pub-id-type="pmid">33912183</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacome-Galarza</surname><given-names>CE</given-names></name><name><surname>Percin</surname><given-names>GI</given-names></name><name><surname>Muller</surname><given-names>JT</given-names></name><name><surname>Mass</surname><given-names>E</given-names></name><name><surname>Lazarov</surname><given-names>T</given-names></name><name><surname>Eitler</surname><given-names>J</given-names></name><name><surname>Rauner</surname><given-names>M</given-names></name><name><surname>Yadav</surname><given-names>VK</given-names></name><name><surname>Crozet</surname><given-names>L</given-names></name><name><surname>Bohm</surname><given-names>M</given-names></name><name><surname>Loyher</surname><given-names>PL</given-names></name><name><surname>Karsenty</surname><given-names>G</given-names></name><name><surname>Waskow</surname><given-names>C</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Developmental origin, functional maintenance and genetic rescue of osteoclasts</article-title><source>Nature</source><volume>568</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1105-7</pub-id><pub-id pub-id-type="pmid">30971820</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>PA</given-names></name><name><surname>Curiac</surname><given-names>D</given-names></name><name><surname>Lazou Ahrén</surname><given-names>I</given-names></name><name><surname>Hansson</surname><given-names>F</given-names></name><name><surname>Martinsson Niskanen</surname><given-names>T</given-names></name><name><surname>Sjögren</surname><given-names>K</given-names></name><name><surname>Ohlsson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Probiotic treatment using a mix of three lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>The Lancet Rheumatology</source><volume>1</volume><fpage>e154</fpage><lpage>e162</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(19)30068-2</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Mulle</surname><given-names>JG</given-names></name><name><surname>Pacifici</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Osteomicrobiology: the influence of gut microbiota on bone in health and disease</article-title><source>Bone</source><volume>115</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2017.04.009</pub-id><pub-id pub-id-type="pmid">28433758</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiesel</surname><given-names>JR</given-names></name><name><surname>Buchwald</surname><given-names>ZS</given-names></name><name><surname>Aurora</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cross-presentation by osteoclasts induces FOXP3 in CD8+ T cells</article-title><source>Journal of Immunology</source><volume>182</volume><fpage>5477</fpage><lpage>5487</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803897</pub-id><pub-id pub-id-type="pmid">19380796</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Inui</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Suematsu</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>E</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>H</given-names></name><name><surname>Matozaki</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Takayanagi</surname><given-names>H</given-names></name><name><surname>Takai</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis</article-title><source>Nature</source><volume>428</volume><fpage>758</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/nature02444</pub-id><pub-id pub-id-type="pmid">15085135</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawenius</surname><given-names>L</given-names></name><name><surname>Colldén</surname><given-names>H</given-names></name><name><surname>Horkeby</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Grahnemo</surname><given-names>L</given-names></name><name><surname>Vandenput</surname><given-names>L</given-names></name><name><surname>Ohlsson</surname><given-names>C</given-names></name><name><surname>Sjögren</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A probiotic mix partially protects against castration-induced bone loss in male mice</article-title><source>The Journal of Endocrinology</source><volume>254</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1530/JOE-21-0408</pub-id><pub-id pub-id-type="pmid">35661635</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lézot</surname><given-names>F</given-names></name><name><surname>Chesneau</surname><given-names>J</given-names></name><name><surname>Navet</surname><given-names>B</given-names></name><name><surname>Gobin</surname><given-names>B</given-names></name><name><surname>Amiaud</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Castaneda</surname><given-names>B</given-names></name><name><surname>Berdal</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>CG</given-names></name><name><surname>Rédini</surname><given-names>F</given-names></name><name><surname>Heymann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid</article-title><source>Bone</source><volume>73</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2014.12.011</pub-id><pub-id pub-id-type="pmid">25532478</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Tawfeek</surname><given-names>H</given-names></name><name><surname>Bedi</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>KY</given-names></name><name><surname>Zayzafoon</surname><given-names>M</given-names></name><name><surname>Weitzmann</surname><given-names>MN</given-names></name><name><surname>Pacifici</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand</article-title><source>PNAS</source><volume>108</volume><fpage>768</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1073/pnas.1013492108</pub-id><pub-id pub-id-type="pmid">21187391</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Chassaing</surname><given-names>B</given-names></name><name><surname>Tyagi</surname><given-names>AM</given-names></name><name><surname>Vaccaro</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Darby</surname><given-names>TM</given-names></name><name><surname>Weitzmann</surname><given-names>MN</given-names></name><name><surname>Mulle</surname><given-names>JG</given-names></name><name><surname>Gewirtz</surname><given-names>AT</given-names></name><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Pacifici</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>2049</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1172/JCI86062</pub-id><pub-id pub-id-type="pmid">27111232</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>TH</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Hou</surname><given-names>YY</given-names></name><name><surname>Shen</surname><given-names>SN</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>C-Type lectin receptor-mediated immune recognition and response of the microbiota in the gut</article-title><source>Gastroenterology Report</source><volume>7</volume><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1093/gastro/goz028</pub-id><pub-id pub-id-type="pmid">31687150</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Boer</surname><given-names>CG</given-names></name><name><surname>Oei</surname><given-names>L</given-names></name><name><surname>Medina-Gomez</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The gut microbiome: a new frontier in musculoskeletal research</article-title><source>Current Osteoporosis Reports</source><volume>19</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/s11914-021-00675-x</pub-id><pub-id pub-id-type="pmid">33864574</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-Seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madel</surname><given-names>MB</given-names></name><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Rouleau</surname><given-names>M</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel reliable and efficient procedure for purification of mature osteoclasts allowing functional assays in mouse cells</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2567</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02567</pub-id><pub-id pub-id-type="pmid">30450105</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madel</surname><given-names>M-B</given-names></name><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>de Vries</surname><given-names>TJ</given-names></name><name><surname>Teti</surname><given-names>A</given-names></name><name><surname>Apparailly</surname><given-names>F</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immune function and diversity of osteoclasts in normal and pathological conditions</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1408</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01408</pub-id><pub-id pub-id-type="pmid">31275328</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madel</surname><given-names>MB</given-names></name><name><surname>Ibáñez</surname><given-names>L</given-names></name><name><surname>Ciucci</surname><given-names>T</given-names></name><name><surname>Halper</surname><given-names>J</given-names></name><name><surname>Rouleau</surname><given-names>M</given-names></name><name><surname>Boutin</surname><given-names>A</given-names></name><name><surname>Hue</surname><given-names>C</given-names></name><name><surname>Duroux-Richard</surname><given-names>I</given-names></name><name><surname>Apparailly</surname><given-names>F</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Blin-Wakkach</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of <italic>cx3cr1</italic></article-title><source>eLife</source><volume>9</volume><elocation-id>e54493</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.54493</pub-id><pub-id pub-id-type="pmid">32400390</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-López</surname><given-names>M</given-names></name><name><surname>Iborra</surname><given-names>S</given-names></name><name><surname>Conde-Garrosa</surname><given-names>R</given-names></name><name><surname>Mastrangelo</surname><given-names>A</given-names></name><name><surname>Danne</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>ER</given-names></name><name><surname>Reid</surname><given-names>DM</given-names></name><name><surname>Gaboriau-Routhiau</surname><given-names>V</given-names></name><name><surname>Chaparro</surname><given-names>M</given-names></name><name><surname>Lorenzo</surname><given-names>MP</given-names></name><name><surname>Minnerup</surname><given-names>L</given-names></name><name><surname>Saz-Leal</surname><given-names>P</given-names></name><name><surname>Slack</surname><given-names>E</given-names></name><name><surname>Kemp</surname><given-names>B</given-names></name><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>Dzionek</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>MJ</given-names></name><name><surname>Rupérez</surname><given-names>FJ</given-names></name><name><surname>Cerf-Bensussan</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>Bernardo</surname><given-names>D</given-names></name><name><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name><surname>Sancho</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Microbiota sensing by mincle-syk axis in dendritic cells regulates interleukin-17 and -22 production and promotes intestinal barrier integrity</article-title><source>Immunity</source><volume>50</volume><fpage>446</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.12.020</pub-id><pub-id pub-id-type="pmid">30709742</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCabe</surname><given-names>LR</given-names></name><name><surname>Irwin</surname><given-names>R</given-names></name><name><surname>Schaefer</surname><given-names>L</given-names></name><name><surname>Britton</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Probiotic use decreases intestinal inflammation AND increases BONE density in healthy male but not female mice</article-title><source>Journal of Cellular Physiology</source><volume>228</volume><fpage>1793</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1002/jcp.24340</pub-id><pub-id pub-id-type="pmid">23389860</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merck</surname><given-names>E</given-names></name><name><surname>Gaillard</surname><given-names>C</given-names></name><name><surname>Gorman</surname><given-names>DM</given-names></name><name><surname>Montero-Julian</surname><given-names>F</given-names></name><name><surname>Durand</surname><given-names>I</given-names></name><name><surname>Zurawski</surname><given-names>SM</given-names></name><name><surname>Menetrier-Caux</surname><given-names>C</given-names></name><name><surname>Carra</surname><given-names>G</given-names></name><name><surname>Lebecque</surname><given-names>S</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Bates</surname><given-names>EEM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>OSCAR is an fcrgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells</article-title><source>Blood</source><volume>104</volume><fpage>1386</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-03-0850</pub-id><pub-id pub-id-type="pmid">15155468</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mócsai</surname><given-names>A</given-names></name><name><surname>Humphrey</surname><given-names>MB</given-names></name><name><surname>Van Ziffle</surname><given-names>JAG</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Burghardt</surname><given-names>A</given-names></name><name><surname>Spusta</surname><given-names>SC</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name><name><surname>Nakamura</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The immunomodulatory adapter proteins DAP12 and fc receptor gamma-chain (fcrgamma) regulate development of functional osteoclasts through the syk tyrosine kinase</article-title><source>PNAS</source><volume>101</volume><fpage>6158</fpage><lpage>6163</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401602101</pub-id><pub-id pub-id-type="pmid">15073337</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moré</surname><given-names>MI</given-names></name><name><surname>Swidsinski</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review</article-title><source>Clinical and Experimental Gastroenterology</source><volume>8</volume><fpage>237</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.2147/CEG.S85574</pub-id><pub-id pub-id-type="pmid">26316791</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>AG</given-names></name><name><surname>Sundh</surname><given-names>D</given-names></name><name><surname>Bäckhed</surname><given-names>F</given-names></name><name><surname>Lorentzon</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial</article-title><source>Journal of Internal Medicine</source><volume>284</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1111/joim.12805</pub-id><pub-id pub-id-type="pmid">29926979</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochi</surname><given-names>S</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Gober</surname><given-names>HJ</given-names></name><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Takai</surname><given-names>T</given-names></name><name><surname>Miyasaka</surname><given-names>N</given-names></name><name><surname>Takayanagi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pathological role of osteoclast costimulation in arthritis-induced bone loss</article-title><source>PNAS</source><volume>104</volume><fpage>11394</fpage><lpage>11399</lpage><pub-id pub-id-type="doi">10.1073/pnas.0701971104</pub-id><pub-id pub-id-type="pmid">17592115</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohlsson</surname><given-names>C</given-names></name><name><surname>Engdahl</surname><given-names>C</given-names></name><name><surname>Fåk</surname><given-names>F</given-names></name><name><surname>Andersson</surname><given-names>A</given-names></name><name><surname>Windahl</surname><given-names>SH</given-names></name><name><surname>Farman</surname><given-names>HH</given-names></name><name><surname>Movérare-Skrtic</surname><given-names>S</given-names></name><name><surname>Islander</surname><given-names>U</given-names></name><name><surname>Sjögren</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Probiotics protect mice from ovariectomy-induced cortical bone loss</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e92368</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092368</pub-id><pub-id pub-id-type="pmid">24637895</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Almeida</surname><given-names>V</given-names></name><name><surname>Yılmaz</surname><given-names>M</given-names></name><name><surname>Teixeira</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Saccharomyces boulardii: what makes it tick as successful probiotic?</article-title><source>Journal of Fungi</source><volume>6</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.3390/jof6020078</pub-id><pub-id pub-id-type="pmid">32512834</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park-Min</surname><given-names>KH</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Antoniv</surname><given-names>T</given-names></name><name><surname>Reid</surname><given-names>AC</given-names></name><name><surname>Silver</surname><given-names>RB</given-names></name><name><surname>Humphrey</surname><given-names>MB</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Il-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression</article-title><source>Journal of Immunology</source><volume>183</volume><fpage>2444</fpage><lpage>2455</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0804165</pub-id><pub-id pub-id-type="pmid">19625651</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patin</surname><given-names>EC</given-names></name><name><surname>Orr</surname><given-names>SJ</given-names></name><name><surname>Schaible</surname><given-names>UE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Macrophage inducible C-type lectin as a multifunctional player in immunity</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>861</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00861</pub-id><pub-id pub-id-type="pmid">28791019</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Duggal</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>C</given-names></name><name><surname>Hitz</surname><given-names>M</given-names></name><name><surname>Prieto-Alhambra</surname><given-names>D</given-names></name><name><surname>Abrahamsen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Risks and benefits of bisphosphonate therapies</article-title><source>Journal of Cellular Biochemistry</source><volume>117</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1002/jcb.25266</pub-id><pub-id pub-id-type="pmid">26096687</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>PJ</given-names></name><name><surname>Adams</surname><given-names>EL</given-names></name><name><surname>Ozment-Skelton</surname><given-names>T</given-names></name><name><surname>Gonzalez</surname><given-names>AJ</given-names></name><name><surname>Goldman</surname><given-names>MP</given-names></name><name><surname>Lockhart</surname><given-names>BE</given-names></name><name><surname>Barker</surname><given-names>LA</given-names></name><name><surname>Breuel</surname><given-names>KF</given-names></name><name><surname>Deponti</surname><given-names>WK</given-names></name><name><surname>Kalbfleisch</surname><given-names>JH</given-names></name><name><surname>Ensley</surname><given-names>HE</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>314</volume><fpage>1079</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1124/jpet.105.085415</pub-id><pub-id pub-id-type="pmid">15976018</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho</surname><given-names>D</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Signaling by myeloid C-type lectin receptors in immunity and homeostasis</article-title><source>Annual Review of Immunology</source><volume>30</volume><fpage>491</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101352</pub-id><pub-id pub-id-type="pmid">22224766</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Sano</surname><given-names>H</given-names></name><name><surname>Iwaki</surname><given-names>D</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Imaizumi</surname><given-names>H</given-names></name><name><surname>Asai</surname><given-names>Y</given-names></name><name><surname>Kuroki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Direct binding of toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A</article-title><source>Journal of Immunology</source><volume>171</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.1.417</pub-id><pub-id pub-id-type="pmid">12817025</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savva</surname><given-names>A</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting Toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>387</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00387</pub-id><pub-id pub-id-type="pmid">24302927</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeling</surname><given-names>M</given-names></name><name><surname>Hillenhoff</surname><given-names>U</given-names></name><name><surname>David</surname><given-names>JP</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Tuckermann</surname><given-names>J</given-names></name><name><surname>Lux</surname><given-names>A</given-names></name><name><surname>Nimmerjahn</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inflammatory monocytes and fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice</article-title><source>PNAS</source><volume>110</volume><fpage>10729</fpage><lpage>10734</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301001110</pub-id><pub-id pub-id-type="pmid">23754379</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>PPC</given-names></name><name><surname>Lerner</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Finding a Toll on the route: the fate of osteoclast progenitors after Toll-like receptor activation</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1663</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01663</pub-id><pub-id pub-id-type="pmid">31379855</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takami</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Rho</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Stimulation by toll-like receptors inhibits osteoclast differentiation</article-title><source>Journal of Immunology</source><volume>169</volume><fpage>1516</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.3.1516</pub-id><pub-id pub-id-type="pmid">12133979</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terciolo</surname><given-names>C</given-names></name><name><surname>Dapoigny</surname><given-names>M</given-names></name><name><surname>Andre</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption</article-title><source>Clinical and Experimental Gastroenterology</source><volume>12</volume><fpage>67</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.2147/CEG.S181590</pub-id><pub-id pub-id-type="pmid">30804678</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>CA</given-names></name><name><surname>Salvage-Jones</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hitchens</surname><given-names>K</given-names></name><name><surname>Butcher</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>RZ</given-names></name><name><surname>Beckhouse</surname><given-names>AG</given-names></name><name><surname>Lo</surname><given-names>YLS</given-names></name><name><surname>Manzanero</surname><given-names>S</given-names></name><name><surname>Cobbold</surname><given-names>C</given-names></name><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Orr</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Lebus</surname><given-names>D</given-names></name><name><surname>Sobieszczuk</surname><given-names>P</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Stow</surname><given-names>J</given-names></name><name><surname>Blanchard</surname><given-names>H</given-names></name><name><surname>Ashman</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to candida albicans</article-title><source>Journal of Immunology</source><volume>180</volume><fpage>7404</fpage><lpage>7413</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.11.7404</pub-id><pub-id pub-id-type="pmid">18490740</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Pi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gut microbiome reveals specific dysbiosis in primary osteoporosis</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>10</volume><elocation-id>160</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00160</pub-id><pub-id pub-id-type="pmid">32373553</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yahara</surname><given-names>Y</given-names></name><name><surname>Barrientos</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>YJ</given-names></name><name><surname>Puviindran</surname><given-names>V</given-names></name><name><surname>Nadesan</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Gibson</surname><given-names>JR</given-names></name><name><surname>Gregory</surname><given-names>SG</given-names></name><name><surname>Diao</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Qadri</surname><given-names>YJ</given-names></name><name><surname>Souma</surname><given-names>T</given-names></name><name><surname>Shinohara</surname><given-names>ML</given-names></name><name><surname>Alman</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair</article-title><source>Nature Cell Biology</source><volume>22</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0437-8</pub-id><pub-id pub-id-type="pmid">31907410</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yahara</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Gracia</surname><given-names>L</given-names></name><name><surname>Alman</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Monocyte/macrophage lineage cells from fetal erythromyeloid progenitors orchestrate bone remodeling and repair</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>622035</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.622035</pub-id><pub-id pub-id-type="pmid">33614650</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>T</given-names></name><name><surname>Ariyoshi</surname><given-names>W</given-names></name><name><surname>Okinaga</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Hosokawa</surname><given-names>R</given-names></name><name><surname>Mochizuki</surname><given-names>S</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Nishihara</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The dectin 1 agonist curdlan regulates osteoclastogenesis by inhibiting nuclear factor of activated T cells cytoplasmic 1 (nfatc1) through syk kinase</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>19191</fpage><lpage>19203</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.551416</pub-id><pub-id pub-id-type="pmid">24821724</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>XK</given-names></name><name><surname>Cheng</surname><given-names>ML</given-names></name><name><surname>Yang</surname><given-names>GZ</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>HJ</given-names></name><name><surname>Hu</surname><given-names>YX</given-names></name><name><surname>Zhu</surname><given-names>LL</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>ZW</given-names></name><name><surname>Liu</surname><given-names>YM</given-names></name><name><surname>Zhang</surname><given-names>BF</given-names></name><name><surname>Mu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Saccharomyces boulardii administration changes gut microbiota and attenuates D-galactosamine-induced liver injury</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>1359</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-01271-9</pub-id><pub-id pub-id-type="pmid">28465509</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaiss</surname><given-names>MM</given-names></name><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Pacifici</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The gut-bone axis: how bacterial metabolites bridge the distance</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>3018</fpage><lpage>3028</lpage><pub-id pub-id-type="doi">10.1172/JCI128521</pub-id><pub-id pub-id-type="pmid">31305265</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of nfatc1</article-title><source>Oncotarget</source><volume>8</volume><fpage>53366</fpage><lpage>53374</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18411</pub-id><pub-id pub-id-type="pmid">28881817</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Kitaura</surname><given-names>H</given-names></name><name><surname>Reeve</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Tybulewicz</surname><given-names>VLJ</given-names></name><name><surname>Shattil</surname><given-names>SJ</given-names></name><name><surname>Ginsberg</surname><given-names>MH</given-names></name><name><surname>Ross</surname><given-names>FP</given-names></name><name><surname>Teitelbaum</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption</article-title><source>The Journal of Cell Biology</source><volume>176</volume><fpage>877</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1083/jcb.200611083</pub-id><pub-id pub-id-type="pmid">17353363</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82037.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yi-Ping</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vmvtb21</institution-id><institution>Tulane University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.01.502322" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.01.502322"/></front-stub><body><p>This important work substantially advances our understanding osteoclast diversity such as inflammatory and state osteoclasts in pathological condition, which was demonstrated by administration of the yeast probiotic Saccharomyces boulardi CNCM I-745 (Sb) in vivo reduced bone loss in OVX but not sham mice by reducing inflammatory osteoclasts, and Sb derivatives specifically inhibited directly the differentiation of inflammatory but not steady state osteoclasts in vitro. The evidence supports the conclusions, through combined transcriptomic profiling, differentiation assays and in vivo analysis in mice to decipher specific traits for inflammatory and steady state osteoclasts. The work will be of broad interest to Immunologists, Microbiologists and Cell biologists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82037.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Li</surname><given-names>Yi-Ping</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vmvtb21</institution-id><institution>Tulane University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ponzetti</surname><given-names>Marco</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01j9p1r26</institution-id><institution>Università degli studi dell'Aquila</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.01.502322">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.08.01.502322v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast <italic>S. boulardii</italic> CNCM I-745 reduces bone loss in osteoporosis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Marco Ponzetti (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>The general objective of this work is the dissection of osteoclast diversity; in particular, the authors intend to identify the specific features and properties that distinguish inflammatory and steady-state (tolerogenic) osteoclasts. To this end, the authors perform a transcriptional analysis of inflammatory and tolerogenic osteoclasts and identify the pattern recognition receptors TLR2, Dectin-1, and Mincle as differentially expressed genes. Agonists of these receptors or yeast probiotics regulating the elicited mechanisms in vitro and in vivo caused a specific inhibition of the differentiation of inflammatory rather than tolerogenic osteoclasts, thus highlighting the preferential use of different differentiation pathways by the two distinct osteoclast populations.</p><p>The project is based on the previous knowledge and know-how of the authors on this peculiar skeletal cell population. The work is well conceived; the experiments are clearly designed and exploit state-of-the-art technologies. The results confirm the heterogeneity of osteoclasts and provide new insights in this respect. The in vitro and in vivo studies suggest that osteoclast heterogeneity can be purposedly modulated; which might be useful and advisable for therapeutic purposes. Overall, the work provides hints for further implementation and future broad applications to diseases featuring pathological bone loss. The osteoclasts are generated in vitro in the presence of M-CSF and RANKL to induce tolerogenic osteoclasts or GM-CSF / Il-4 to generate inflammatory osteoclasts. The demonstration of these cell populations in the S.b. treated mice in vivo is not present. The author tried to tackle this, by analyzing the differentiation potential of bone marrow progenitor cells of S.b. treated animals, which provides some information. The effect on tolerogenic osteoclasts could have been further evaluated, whether they are not affected at all, or whether there are also effects.</p><p>Essential revisions:</p><p>1. Please briefly describe biocodex in the disclosure section and provide details of the connection, including the fact that biocodex is one of the funding bodies of the work. 3g/kg thrice a week seems like quite a high dosage, do the authors expect Sb to be effective also at lower dosages in humans? The authors could probably provide references where high-dose probiotics in mice then proved effective at lower doses in humans in the Discussion section. Do the authors have any data on the effectiveness of Sb in IBD-dependent bone loss? Could any of the identified markers be used to sort mature inflammatory osteoclasts from tolerogenic osteoclasts? (see reviewer 1's comments)</p><p>2. It would be helpful to understand the localization of the different cell types in vivo. Could the authors use a co-staining approach for osteoclast markers and the PPRs to identify this subpopulation in vivo? That would certainly strengthen the message of the manuscript. (see reviewer 2's comments)</p><p>3. By evaluating the expression profiling it was not clear, whether an unfiltered GO analysis of DEGs would reveal C-type lectin receptor signaling as well, or whether other discriminating factors would be superior. As I understood in Figure 1e there was already a pre-selection of osteoclast/resorptive associated genes. (see reviewer 2's comments)</p><p>4. The functional studies of the inhibition of PPRs seemed to decrease also strongly in cell numbers in general (Figure 4 a-d), suggesting that also progenitor cells are affected. The authors should address this through the analysis of earlier time points. (see reviewer 2's comments)</p><p>5. There are already publications on PPRs and their function on osteoclasts, e.g. for the Mincle and Dectin-1 and in these publications, the effects are claimed to be more general on osteoclasts. In part, even opposite effects are reported. The effects of silencing of these receptors on the &quot;tolerogenic cells&quot; and the consequence on resorption should be therefore more clear. (see reviewer 2's comments)</p><p>6. The authors talk about decreased osteoclast numbers in the histomorphometry, but the osteoclast area is shown in Figure 2f. The authors should show the numbers of multinucleated cells as well. (see reviewer 2's comments)</p><p>7. The failure to rescue cortical parameters by S.b. is intriguing, the authors should discuss it. (see reviewer 2's comments)</p><p>8. There is an apparent strong trend that osteocytes are increased in supplementary figure 2c. The authors should discuss it since they also mention trends (p=0.09) elsewhere. (see reviewer 2's comments)</p><p>9. Page 9, lines 313-314: in line with the references here provided, the authors may quantify these cytokines in their experimental conditions. (see reviewer 3's comments)</p><p>10. Please show the level of gene silencing obtained with siRNA targeting TLR2 (and control siRNA as well). (see reviewer 3's comments)</p><p>11. In the supplementary figure 2, please provide also cortical porosity data (panel a) and representative images of Osterix and Sost IHC staining for the control groups SHAM and SHAM+Sb. Please detail how osteoblast and osteocyte count was performed (how many sections per mouse? Quantization on the entire tissue section or a number of fields?) (see reviewer 3's comments)</p><p>12. Pages 12-13, Primary cell culture and osteoclast differentiation: please specify the duration of the osteoclast differentiation assay and the frequency of PRR agonist supplementation into the culture. Also, please indicate at which time point OCL activity was measured. (see reviewer 3's comments)</p><p>13. In general, we suggest the authors present all the data as scatter plots with bars (where applicable), as already done in a number of panels. (see reviewer 3's comments)</p><p>14. A point-by-point response to all three reviewers' comments.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The report presented by Madel/Halper and colleagues is very well-written, logical, easy to read, and with a very good flow and pace. All the experiments presented are scientifically sound and the conclusions are not overstated. As a person working in the field, I agree with the authors that osteoclast heterogeneity is an under-investigated and underestimated issue and that more research is needed to understand how the different sub-populations of osteoclasts participate in bone loss in pathological conditions. In this report, the authors first explore osteoclast heterogeneity using RNAseq and miRNA analyses, and then, find that specific pattern-recognition receptors are overexpressed in inflammatory osteoclasts compared to tolerogenic osteoclasts, and that this difference can also be observed in vivo in OVX mice, they proceed to administer a commercially-available strain of the probiotic yeast S. boulardii to OVX mice, observing prevention of the ovariectomy-induced bone loss, with an effect that is not oestrogen-mediated since uterus weight is comparable between treated and untreated mice. The report deserves publication in <italic>eLife</italic>, I only have a few comments that I hope will improve the quality of the manuscript even more.</p><p>Figure 2d type size is inconsistent and in general in the same figure sometimes the font size varies.</p><p>Figure 4e 10μg goes inside the space of the figure.</p><p>Supp figure 2b missing measuring units for obs and ocs.</p><p>Line 400 should read {greater than or equal to}.</p><p>Line 468 please specify how the region of interest was selected and the software and algorithms used for analysis (e.g. bruker CTan, thresholding method global).</p><p>Line 479 for how long?</p><p>A table collecting all antibodies used (also with RRID) and relative concentrations would be helpful as a supplementary. The same could be said for primer sequences/Taqman assay ID.s.</p><p>Line 533 what is the concentration of saponin 1X?</p><p>Please briefly describe biocodex in the disclosure section and provide details of the connection, including the fact that biocodex is one of the funding bodies of the work.</p><p>3g/kg thrice a week seems like quite a high dosage, do the authors expect Sb to be effective also at lower dosages in humans? The authors could probably provide references where high-dose probiotics in mice then proved effective at lower doses in humans in the Discussion section.</p><p>Do the authors have any data on the effectiveness of Sb in IBD-dependent bone loss?</p><p>Could any of the identified markers be used to sort mature inflammatory osteoclasts from tolerogenic osteoclasts?</p><p>Line 241 maybe the authors could show this data in a supplementary figure.</p><p>Did the authors evaluate the serum levels of IL4 and IL10 in OVX mice treated with Sb? Up to the authors' discretion but it would be interesting to know this, since if they are affected, they may play a part in the phenotype rescue observed, and if they are not, it would be even more interesting because everything would be caused by β-glucans or other compounds contained in the probiotics.</p><p>Were there any side effects to the probiotic treatment?</p><p>Figure 2D and all others: authors should also show the statistical comparisons between Sham-Sb and OVX-Sb.</p><p>Usually, osteoclasts are evaluated histomorphometrically using Oc.S/BS and Oc.N/BS – is there a specific reason why the authors used Tracp+ Area/Bone surface for these analyses?</p><p>It would be interesting to perform GSEA on these datasets as well, which might lead to further findings and useful data for the authors.</p><p>Again, congratulations to the authors for an interesting and well-done report.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. It would be helpful to understand the localization of the different cell types in vivo. Could the authors use a co-staining approach for osteoclast markers and the PPRs to identify this subpopulation in vivo? That would certainly strengthen the message of the manuscript.</p><p>2. By evaluating the expression profiling it was not clear, whether an unfiltered GO analysis of DEGs would reveal C-type lectin receptor signaling as well, or whether other discriminating factors would be superior. As I understood in Figure 1e there was already a pre-selection of osteoclast/resorptive associated genes.</p><p>3. The functional studies of the inhibition of PPRs seemed to decrease also strongly in cell numbers in general (Figure 4 a-d), suggesting that also progenitor cells are affected. The authors should address this through the analysis of earlier time points.</p><p>4. There are already publications on PPRs and their function on osteoclasts, e.g. for the Mincle and Dectin-1 and in these publications, the effects are claimed to be more general on osteoclasts. In part, even opposite effects are reported. The effects of silencing these receptors on the &quot;tolerogenic cells&quot; and the consequence on resorption should be therefore more clear.</p><p>5. The authors talk about decreased osteoclast numbers in the histomorphometry, but the osteoclast area is shown in Figure 2f. The authors should show the numbers of multinucleated cells as well.</p><p>6. The failure to rescue cortical parameters by S.b. is intriguing, the authors should discuss it.</p><p>7. There is an apparent strong trend that osteocytes are increased in supplementary figure 2c. The authors should discuss it since they also mention trends (p=0.09) elsewhere.</p><p>8. In Figure 3a-d single data points are missing and should be added.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Suggestions to the authors:</p><p>– Additional data:</p><p>Page 9, lines 313-314: in line with the references here provided, the authors may quantify these cytokines in their experimental conditions.</p><p>Please show the level of gene silencing obtained with siRNA targeting TLR2 (and control siRNA as well).</p><p>In supplementary figure 2, please provide also cortical porosity data (panel a) and representative images of Osterix and Sost IHC staining for the control groups SHAM and SHAM+Sb. Please detail how osteoblast and osteocyte count was performed (how many sections per mouse? Quantization on the entire tissue section or a number of fields?).</p><p>– Method description:</p><p>Pages 12-13, Primary cell culture and osteoclast differentiation: please specify the duration of the osteoclast differentiation assay and the frequency of PRR agonist supplementation into the culture. Also, please indicate at which time point OCL activity was measured.</p><p>– Figure legends: Actually, we think referring to the supplementary figures in the legend to the main figures is confounding. We think the legend should describe only what is displayed in the corresponding figure.</p><p>– Text edits:</p><p>Page 3, line 60: HETEROGENEOUS instead of ETEROGENEOUS; line 78: i-OCLs (plural) instead of i-OCL; line 87: you can use the acronym i-OCLs here since it has been already introduced earlier.</p><p>Page 4, line 108: maybe use ANALYSIS instead of APPROACH; line 110: &quot;and representing&quot;: we think AND can be deleted; line 112: &quot;between BOTH OCL subsets&quot;: we think &quot;between THE TWO OCL subsets&quot; is more appropriate.</p><p>Page 5, line 150: IN HERE should be HEREIN; line 155: SHAM OCLs: we would prefer &quot;OCLs derived from SHAM mice&quot;.</p><p>Page 7, line 219: &quot;to a lesser extent&quot; this can be deleted from our point of view; in fact, in both treatment groups (SHAM and OVX) the OCL % seems to be reduced by 50%; line 221: the term KINASE can be deleted here.</p><p>Page 8, line 247: the proportion OF; line 249: &quot;Lastly,…(Figure 4g)&quot; we are not convinced this statement is correctly placed here, since it refers to the result of an experiment described earlier, while the present paragraph deals with the effect of Sb-CM.</p><p>Page 9, line 283: &quot;recognized by&quot; can be replaced by FOR, in line with the construction used in the previous line; line 293: &quot;in A several OF gastrointestinal disorders&quot; should be &quot;in several gastrointestinal disorders&quot;, or &quot;in a SERIES (VARIETY or similar term) of&quot;; line 312: &quot;Sb IT has been described&quot; delete IT.</p><p>Page 10, line 344: use DEMONSTRATED instead of IDENTIFIED; line 349: please check this line.</p><p>Page 12, line 365: &quot;assigned into two groups&quot; we suggest &quot;DIVIDED INTO two groups&quot;; lines 371-372: &quot;french ministry of health. Higher education and research&quot; all initials in capital letters.</p><p>Page 13, line 404 ALIZARINE should be ALIZARIN.</p><p>Page 15, line 499: SERIC should be SERUM.</p><p>Page 24, line 834: &quot;FACS plots&quot; should be &quot;histograms&quot;.</p><p>Page 25, line 855: if we get it correct from the figure, it seems that the number of replicates is n{greater than or equal to}5 (not n=5); lines 860-861: n=?. Figure 4, panels a-c: please indicate in the legend what is represented in the graphs: mean {plus minus} s.d.? In the text and in the figures please confirm to the unit mL (not ml; at present, both are used here).</p><p>Figure 4, panel b: ZYMOZAN should be ZYMOSAN; panel h: it is not necessary to indicate the name of the specific PRR agonist used on top of each graph because it is indicated under each graph.</p><p>Figure 5, panel c and Figure 6, panel d: MHC2 should be MHC-II.</p><p>Legend to supplementary figure 2: invert cortical bone surface/bone volume and cortical thickness, in accordance with the order of the graphs in the figure; the last line: conditionned should be conditioned.</p><p>– Figures:</p><p>In general, we suggest the authors present all the data as scatter plots with bars (where applicable), as already done in a number of panels.</p><p>Figure 1, panel j, first graph: normalized to…?</p><p>Figure 2: we think it could be interesting to see a representative plot, to visualize double positive cells.</p><p>Figure 3, panels e and f: use &quot;SHAM+Sb&quot; and &quot;OVX+Sb&quot;, in line with the other panels and figures.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82037.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The report presented by Madel/Halper and colleagues is very well-written, logical, easy to read, and with a very good flow and pace. All the experiments presented are scientifically sound and the conclusions are not overstated. As a person working in the field, I agree with the authors that osteoclast heterogeneity is an under-investigated and underestimated issue and that more research is needed to understand how the different sub-populations of osteoclasts participate in bone loss in pathological conditions. In this report, the authors first explore osteoclast heterogeneity using RNAseq and miRNA analyses, and then, find that specific pattern-recognition receptors are overexpressed in inflammatory osteoclasts compared to tolerogenic osteoclasts, and that this difference can also be observed in vivo in OVX mice, they proceed to administer a commercially-available strain of the probiotic yeast S. boulardii to OVX mice, observing prevention of the ovariectomy-induced bone loss, with an effect that is not oestrogen-mediated since uterus weight is comparable between treated and untreated mice. The report deserves publication in eLife, I only have a few comments that I hope will improve the quality of the manuscript even more.</p></disp-quote><p>We thank the reviewer for it's positive comments.</p><disp-quote content-type="editor-comment"><p>Figure 2d type size is inconsistent and in general in the same figure sometimes the font size varies.</p><p>Figure 4e 10μg goes inside the space of the figure.</p><p>Supp figure 2b missing measuring units for obs and ocs.</p></disp-quote><p>All these points have been corrected in the corresponding figures.</p><disp-quote content-type="editor-comment"><p>Line 400 should read {greater than or equal to}.</p></disp-quote><p>This has been corrected.</p><disp-quote content-type="editor-comment"><p>Line 468 please specify how the region of interest was selected and the software and algorithms used for analysis (e.g. bruker CTan, thresholding method global).</p></disp-quote><p>The requested information has been added in the material and methods section<italic>.</italic></p><disp-quote content-type="editor-comment"><p>Line 479 for how long?</p></disp-quote><p>The information has been added in the material and methods section.</p><disp-quote content-type="editor-comment"><p>A table collecting all antibodies used (also with RRID) and relative concentrations would be helpful as a supplementary. The same could be said for primer sequences/Taqman assay ID.s.</p></disp-quote><p>The key resources table has been provided with the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Line 533 what is the concentration of saponin 1X?</p></disp-quote><p>The concentration is 1 g/100 mL. The information has been added in the material and method.</p><disp-quote content-type="editor-comment"><p>Please briefly describe biocodex in the disclosure section and provide details of the connection, including the fact that biocodex is one of the funding bodies of the work.</p></disp-quote><p>As requested, in the competing interest section we have indicated that Biocodex is a pharmaceutical laboratory and we have provided the requested information.</p><disp-quote content-type="editor-comment"><p>3g/kg thrice a week seems like quite a high dosage, do the authors expect Sb to be effective also at lower dosages in humans? The authors could probably provide references where high-dose probiotics in mice then proved effective at lower doses in humans in the Discussion section.</p></disp-quote><p>We agree with the reviewer that the dosage of Sb we used in vivo (~65 mg/mouse corresponding to ~3.10<sup>9</sup> CFU/mouse/day, 3 times a week for 4 weeks) is much higher than the one used in human (200 mg/person/day, corresponding to ~10<sup>10</sup> CFU). However, this range of dose is frequently used in studies evaluating the effects of Sb on chronic diseases in mouse (as for instance in 2 diabetic models in which mice received 0.5×10<sup>8</sup> CFU of Sb/mouse/day for 8 weeks) (https://doi.org/10.1016/j.lfs.2022.120616) or 120mg/mouse/day for 4 weeks (DOI: <ext-link ext-link-type="uri" xlink:href="https://doi-org.insb.bib.cnrs.fr/10.1128/mbio.01011-14">10.1128/mBio.01011-14</ext-link>).</p><p>Interestingly, in the context of osteoporosis, equivalent differences in the dosage of bacterial probiotics used in human and mouse have been reported. For instance, <italic>Lactobacillus</italic> strains were shown to reduce bone loss in osteoporotic at 1x10<sup>9</sup> CFU/ml of drinking water/day (corresponding to about 4,5x10<sup>9</sup> CFU/mouse/day) for 6 weeks, and this protective effect has been confirmed in human with a dose of 10<sup>10</sup> CFU/ patient /day for 1 year (https://doi.org/10.1016/S2665-9913(19)30068-2). Same result was reported for <italic>Lactobacillus</italic> reuteri which is protective in mouse at a dose of 3x10<sup>8</sup> CFU/3 times a week for 4 weeks (https://doi.org/10.1002/jcp.24636) and which reduces bone loss in osteoporotic patients at dose of 1x10<sup>10</sup> CFU/patient/day for 1 year (DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/joim.12805">10.1111/joim.12805</ext-link> ).</p><p>Therefore, based on such studies showing protective effect of probiotics with much lower doses in human compared to mouse, we can assume that lower doses of Sb would also be effective in human, even though the clear answer to this question would require a clinical trial in osteoporotic patients. This has been discussed in the Discussion section of our revised manuscript.</p><disp-quote content-type="editor-comment"><p>Do the authors have any data on the effectiveness of Sb in IBD-dependent bone loss?</p></disp-quote><p>Unfortunately, we don't have any data on the effect of Sb on IBD-dependent bone loss.</p><disp-quote content-type="editor-comment"><p>Could any of the identified markers be used to sort mature inflammatory osteoclasts from tolerogenic osteoclasts?</p></disp-quote><p>From our transcriptomic data we indeed identified markers, including those described here, that we are using to sort and analyse inflammatory and non-inflammatory osteoclasts for new specific properties. However, these new data will be the subject of another manuscript that is in preparation. Therefore we prefer not to include them in our manuscript as we believe it's not essential for this study. We hope the reviewer will understand.</p><disp-quote content-type="editor-comment"><p>Line 241 maybe the authors could show this data in a supplementary figure.</p></disp-quote><p>The requested data on cell apoptosis have been included in Figure 4—figure supplement 1a-c.</p><disp-quote content-type="editor-comment"><p>Did the authors evaluate the serum levels of IL4 and IL10 in OVX mice treated with Sb? Up to the authors' discretion but it would be interesting to know this, since if they are affected, they may play a part in the phenotype rescue observed, and if they are not, it would be even more interesting because everything would be caused by β-glucans or other compounds contained in the probiotics.</p></disp-quote><p>We performed the requested experiment by dosing serum concentration of IL-10 and IL-4 by ELISA. The results showed no significant difference in IL-10 concentration between OVX and OVX+Sb mice (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). This result has been added as data not shown. IL-4 was not detected in any of the conditions.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82037-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Were there any side effects to the probiotic treatment?</p></disp-quote><p>We did not observed any side effects of the probiotic in the treated mice.</p><disp-quote content-type="editor-comment"><p>Figure 2D and all others: authors should also show the statistical comparisons between Sham-Sb and OVX-Sb.</p></disp-quote><p>Figures 2 and 3 have been modified as requested to show the statistical comparisons between Sham-Sb and OVX-Sb.</p><disp-quote content-type="editor-comment"><p>Usually, osteoclasts are evaluated histomorphometrically using Oc.S/BS and Oc.N/BS – is there a specific reason why the authors used Tracp+ Area/Bone surface for these analyses?</p></disp-quote><p>In our hands, TRAcP staining in vivo is usually very intense, which makes it impossible to always see the limit between 2 OCLs and all nuclei, and thus to properly count individually these cells. That's why in all our previous studies, we have always evaluated OCL area and not their number. This approach has already been validated in a number of publications (for instance <italic>=</italic> Mansour et al., Cell research 2011. DOI:10.1038/cr.2011.21; Mansour et al., J Exp Med 2012. DOI:10.1084/jem.20110994; Moukengue B et al. EBioMedicine. 2020. doi: 10.1016/j.ebiom.2020.102704; Guihard P et al. Am J Pathol. 2015. doi: 10.1016/j.ajpath.2014.11.008; Lamoureux F, et al. Nat Commun. 2014. doi: 10.1038/ncomms4511; Gobin B, et al. Int J Cancer. 2015. doi: 10.1002/ijc.29040; Gobin B et al. Cancer Lett. 2014. doi: 10.1016/j.canlet.2013.11.017; Velasco CR, et al. Glycobiology. 2011. doi: 10.1093/glycob/cwr002).</p><p>However, to comply with the reviewer's comment, we modified the text not to talk about OCL number.</p><disp-quote content-type="editor-comment"><p>It would be interesting to perform GSEA on these datasets as well, which might lead to further findings and useful data for the authors.</p></disp-quote><p>This analysis has been performed (see <xref ref-type="table" rid="sa2table1">Author response table 1</xref>). As it gave results equivalent to those presented in figure 1c, we did not include it in the revised manuscript.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene Set Name</th><th align="left" valign="bottom"># Genes in Gene Set (K)</th><th align="left" valign="bottom"># Genes in Overlap (k)</th><th align="left" valign="bottom">k/K</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">FDR q-value</th></tr></thead><tbody><tr><td align="left" valign="bottom">DEFENSE_RESPONSE</td><td align="char" char="." valign="bottom">1816</td><td align="char" char="." valign="bottom">109</td><td align="char" char="." valign="bottom">0.0600</td><td align="char" char="hyphen" valign="bottom">3.16E-47</td><td align="char" char="hyphen" valign="bottom">3.88E-43</td></tr><tr><td align="left" valign="bottom">REGULATION_OF_IMMUNE_SYSTEM_PROCESS</td><td align="char" char="." valign="bottom">1642</td><td align="char" char="." valign="bottom">101</td><td align="char" char="." valign="bottom">0.0615</td><td align="char" char="hyphen" valign="bottom">1.54E-44</td><td align="char" char="hyphen" valign="bottom">9.45E-41</td></tr><tr><td align="left" valign="bottom">INFLAMMATORY_RESPONSE</td><td align="char" char="." valign="bottom">770</td><td align="char" char="." valign="bottom">69</td><td align="char" char="." valign="bottom">0.0896</td><td align="char" char="hyphen" valign="bottom">2.09E-40</td><td align="char" char="hyphen" valign="bottom">8.58E-37</td></tr><tr><td align="left" valign="bottom">CELL_ADHESION</td><td align="char" char="." valign="bottom">1480</td><td align="char" char="." valign="bottom">84</td><td align="char" char="." valign="bottom">0.0568</td><td align="char" char="hyphen" valign="bottom">2.77E-34</td><td align="char" char="hyphen" valign="bottom">8.53E-31</td></tr><tr><td align="left" valign="bottom">IMMUNE_RESPONSE</td><td align="char" char="." valign="bottom">1920</td><td align="char" char="." valign="bottom">94</td><td align="char" char="." valign="bottom">0.0490</td><td align="char" char="hyphen" valign="bottom">2.27E-33</td><td align="char" char="hyphen" valign="bottom">5.57E-30</td></tr><tr><td align="left" valign="bottom">CELL_ACTIVATION</td><td align="char" char="." valign="bottom">1273</td><td align="char" char="." valign="bottom">77</td><td align="char" char="." valign="bottom">0.0605</td><td align="char" char="hyphen" valign="bottom">3.16E-33</td><td align="char" char="hyphen" valign="bottom">6.48E-30</td></tr><tr><td align="left" valign="bottom">BIOLOGICAL_PROCESS_INVOLVED_IN_INTERSPECIES_INTERACTION_BETWEEN_ORGANISMS</td><td align="char" char="." valign="bottom">1835</td><td align="char" char="." valign="bottom">91</td><td align="char" char="." valign="bottom">0.0496</td><td align="char" char="hyphen" valign="bottom">1.07E-32</td><td align="char" char="hyphen" valign="bottom">1.89E-29</td></tr><tr><td align="left" valign="bottom">REGULATION_OF_CELL_ADHESION</td><td align="char" char="." valign="bottom">811</td><td align="char" char="." valign="bottom">60</td><td align="char" char="." valign="bottom">0.0740</td><td align="char" char="hyphen" valign="bottom">1.46E-30</td><td align="char" char="hyphen" valign="bottom">2.24E-27</td></tr><tr><td align="left" valign="bottom">POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS</td><td align="char" char="." valign="bottom">1722</td><td align="char" char="." valign="bottom">85</td><td align="char" char="." valign="bottom">0.0494</td><td align="char" char="hyphen" valign="bottom">2.39E-30</td><td align="char" char="hyphen" valign="bottom">3.26E-27</td></tr><tr><td align="left" valign="bottom">REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS</td><td align="char" char="." valign="bottom">992</td><td align="char" char="." valign="bottom">65</td><td align="char" char="." valign="bottom">0.0655</td><td align="char" char="hyphen" valign="bottom">5.04E-30</td><td align="char" char="hyphen" valign="bottom">6.19E-27</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>Again, congratulations to the authors for an interesting and well-done report.</p></disp-quote><p>We thank the reviewer for it's positive comments.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. It would be helpful to understand the localization of the different cell types in vivo. Could the authors use a co-staining approach for osteoclast markers and the PPRs to identify this subpopulation in vivo? That would certainly strengthen the message of the manuscript.</p></disp-quote><p>We agree with the reviewer that this is an interesting question. However, we have a new article in preparation in which the specific localization and new properties of inflammatory and tolerogenic osteoclasts will be analyzed in detail. Thus, we prefer not to include part of these new data in the present manuscript so as not to limit the interest of this new paper. We hope the reviewer will understand our position.</p><disp-quote content-type="editor-comment"><p>2. By evaluating the expression profiling it was not clear, whether an unfiltered GO analysis of DEGs would reveal C-type lectin receptor signaling as well, or whether other discriminating factors would be superior. As I understood in Figure 1e there was already a pre-selection of osteoclast/resorptive associated genes.</p></disp-quote><p>The reviewer is right, the analysis in former Figure 1e is done on a list of genes preselected from the Kegg pathway mmu04380 (osteoclast differentiation). In line with the reviewer's suggestion, we performed similar analysis on the totality of the genes differentially express between MN-OCLs and DC-OCLs, which also highlighted the c-lectin like receptor pathway. This new analysis has been added in Figure 1d.</p><disp-quote content-type="editor-comment"><p>3. The functional studies of the inhibition of PPRs seemed to decrease also strongly in cell numbers in general (Figure 4 a-d), suggesting that also progenitor cells are affected. The authors should address this through the analysis of earlier time points.</p></disp-quote><p>As requested by the reviewer, we performed a viability assay by measuring the apoptotic cells (Annexin –V+ PI+) by FACS 24 and 48 hours after the addition of agonists. Our results revealed that neither the agonists, nor the Sb-conditioned medium, induced cell apoptosis. These results have been added in Figure 4—figure supplement 1a-d.</p><disp-quote content-type="editor-comment"><p>4. There are already publications on PPRs and their function on osteoclasts, e.g. for the Mincle and Dectin-1 and in these publications, the effects are claimed to be more general on osteoclasts. In part, even opposite effects are reported. The effects of silencing these receptors on the &quot;tolerogenic cells&quot; and the consequence on resorption should be therefore more clear.</p></disp-quote><p>We fully agree with the comment of reviewer. It's true that in the literature, it has been reported that curdlan reduces global osteoclast differentiation through Dectin-1. However, this effect is observed only with high concentrations (range of 10 µg/mL and more) of curdlan (https://doi.org/10.18632/oncotarget.18411) whereas the effect we observed specifically on i-OCLs is already achieved with 10 ng/mL. It has also been reported that the Dectin-1 protein is expressed in BM OCL progenitors but at low levels (https://doi.org/10.1074/jbc.M114.551416) and that Dectin-1 activation by curdlan efficiently reduces OCL formation from RAW cells only when cells are transfected with Dectin-1 (https://doi.org/10.1074/jbc.M114.551416). Although these studies have already been discussed in our manuscript, we have expanded this point in the revised version (see &quot;discussion&quot;).</p><p>Regarding Mincle, we also agree that opposite effects have been reported in the literature and indeed stimulation of Mincle by necrotic osteocytes stimulates OCL differentiation (<italic>doi: 10.1172/JCI134214</italic>). We therefore performed in vitro experiments on BM cells from Mincle KO mice and microscanner analysis of these mice. For the microscanner, we obtained results similar to those of Andreev et al. 2020, with an increased bone mass in Mincle (Clec4e) KO mice. However, for the in vitro experiments, our results are divergent with this study. We performed osteoclastogenic differentiation in vitro from total BM cells, BM-derived DCs and BM monocytes, and we observed a tendency to an increased osteoclastogenesis, whatever the OCL progenitor we used. This discrepancy may be explain by the use of a different protocol for osteoclastogenesis as we start the differentiation adding M-CSF and RANKL together, while Andreev et al. 2020 add M-CSF first and 2 days later they add RANKL. Furthermore, we tested the effect of the Mincle agonist GlcC14C18 on osteoclastogenesis from Mincle KO DCs and our results show that the inhibition of osteoclastogenesis is reduced compared to WT confirming the implication of Mincle in this inhibition.</p><p>Therefore, these observations revealed the complex effects of Mincle on osteoclastogenesis, as already shown on other monocytic cells. These new results have been added in in Figure 4-Suppl Figure 2 and commented in the discussion.</p><p>Lastly, as requested, we performed additional experiment to assess the effect of agonist on the resorption capacity of tolerogenic OCLs, which did not reveal any significant effect. The data were added in Figure 4—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>5. The authors talk about decreased osteoclast numbers in the histomorphometry, but the osteoclast area is shown in Figure 2f. The authors should show the numbers of multinucleated cells as well.</p></disp-quote><p>As explained for reviewer 1, in our hands, TRAcP staining in vivo is usually very intense, which makes it impossible to always see the limit between 2 OCLs and all nuclei, and thus to properly count individually these cells. That's why in all our previous studies, we have always evaluated OCL area and not their number. This approach has already been validated in a number of publications (for instance = Mansour et al., Cell research 2011. DOI:10.1038/cr.2011.21; Mansour et al., J Exp Med 2012. DOI:10.1084/jem.20110994; Moukengue B et al. EBioMedicine. 2020. doi: 10.1016/j.ebiom.2020.102704; Guihard P et al. Am J Pathol. 2015. doi: 10.1016/j.ajpath.2014.11.008; Lamoureux F, et al. Nat Commun. 2014. doi: 10.1038/ncomms4511; Gobin B, et al. Int J Cancer. 2015. doi: 10.1002/ijc.29040; Gobin B et al. Cancer Lett. 2014. doi: 10.1016/j.canlet.2013.11.017; Velasco CR, et al. Glycobiology. 2011. doi: 10.1093/glycob/cwr002).</p><p>However, to comply with the reviewer's comment, we modified the text not to talk about OCL number.</p><disp-quote content-type="editor-comment"><p>6. The failure to rescue cortical parameters by S.b. is intriguing, the authors should discuss it.</p></disp-quote><p>Such a lack of effect on cortical bone has also been reported in OVX mice treated with bacterial probiotics (<italic>McCabe et al., 2013, DOI 10.1002/jcp.24340; Britton et al., 2014, DOI 10.1002/jcp.24636 ; Lawenius et al., 2022, DOI 10.1530/JOE-21-0408</italic> …). The reasons are not clear but it could be due to a too short period of treatment, a starting point too late after surgery, or a preferential location of certain OCL subtypes in the trabecular versus cortical bone.</p><p>This point has been commented in the &quot;results&quot; section.</p><disp-quote content-type="editor-comment"><p>7. There is an apparent strong trend that osteocytes are increased in supplementary figure 2c. The authors should discuss it since they also mention trends (p=0.09) elsewhere.</p></disp-quote><p>The comparison of osteocyte numbers between the OVX and OVX+Sb groups yielded a p=0.22, far from significance. In contrast, the pVal mentioned by the reviewer (Figure 3c-d) are lower, despite not reaching significance (p=0.09 and 0.08 for butyrate and lactate, respectively). Moreover, the different metabolites we measured all showed a similar pattern of variation, in particular an increase after Sb treatment in OVX mice. It's because they all varied the same way that we discussed this tendency in this figure.</p><disp-quote content-type="editor-comment"><p>8. In Figure 3a-d single data points are missing and should be added.</p></disp-quote><p>Single data points have been added in all the figures.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Suggestions to the authors:</p><p>– Additional data:</p><p>Page 9, lines 313-314: in line with the references here provided, the authors may quantify these cytokines in their experimental conditions.</p></disp-quote><p>As explained for reviewer 1, We performed the requested experiment by dosing by ELISA serum concentration of IL-10 and IL-4. The results showed no significant difference in IL-10 concentration between OVX and OVX+Sb mice (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). This result has been added as data not shown.</p><p>IL-4 was not detected in any of the conditions.</p><disp-quote content-type="editor-comment"><p>Please show the level of gene silencing obtained with siRNA targeting TLR2 (and control siRNA as well).</p></disp-quote><p>As requested, these data have been added in Figure 4—figure supplement 1e.</p><disp-quote content-type="editor-comment"><p>In supplementary figure 2, please provide also cortical porosity data (panel a) and representative images of Osterix and Sost IHC staining for the control groups SHAM and SHAM+Sb. Please detail how osteoblast and osteocyte count was performed (how many sections per mouse? Quantization on the entire tissue section or a number of fields?).</p></disp-quote><p>Unfortunately, it is not possible to provide data on cortical porosity with the parameters that have been recorded in the µCT facility. And we don't have anymore bone sample left to repeat the anaysis for cortical porosity. We hope the reviewer will understand.</p><p>The images of Osterix and Sost staining has been added for SHAM and SHAM+Sb groups in Figure 2-supplement figure 2. The requested information on cell count and quantization has been added in the material and method section.</p><disp-quote content-type="editor-comment"><p>– Method description:</p><p>Pages 12-13, Primary cell culture and osteoclast differentiation: please specify the duration of the osteoclast differentiation assay and the frequency of PRR agonist supplementation into the culture. Also, please indicate at which time point OCL activity was measured.</p></disp-quote><p>The requested information has been added in the material and method section.</p><disp-quote content-type="editor-comment"><p>– Figure legends: Actually, we think referring to the supplementary figures in the legend to the main figures is confounding. We think the legend should describe only what is displayed in the corresponding figure.</p></disp-quote><p>This is a request of the journal. It is stated in the author guide that &quot;Figure Supplements should be referred to in the legend of the associated primary figure&quot;.</p><disp-quote content-type="editor-comment"><p>Page 7, line 219: &quot;to a lesser extent&quot; this can be deleted from our point of view; in fact, in both treatment groups (SHAM and OVX) the OCL % seems to be reduced by 50%; line 221: the term KINASE can be deleted here.</p></disp-quote><p>We removed &quot;to a lesser extend&quot;. The other points have been modified in the text.</p><disp-quote content-type="editor-comment"><p>Page 8, line 247: the proportion OF; line 249: &quot;Lastly,…(Figure 4g)&quot; we are not convinced this statement is correctly placed here, since it refers to the result of an experiment described earlier, while the present paragraph deals with the effect of Sb-CM.</p></disp-quote><p>This sentence also refers to Sb-CM, which, we agree, was not clearly indicated. This has been corrected. Morevoer, we deleted the SB-CM data from figure 4g to put it as a new figure (6b) to have all the data on Sb-CM in the same figure.</p><disp-quote content-type="editor-comment"><p>Page 25, line 855: if we get it correct from the figure, it seems that the number of replicates is n{greater than or equal to}5 (not n=5); lines 860-861: n=?. Figure 4, panels a-c: please indicate in the legend what is represented in the graphs: mean {plus minus} s.d.? In the text and in the figures please confirm to the unit mL (not ml; at present, both are used here).</p><p>Figure 4, panel b: ZYMOZAN should be ZYMOSAN; panel h: it is not necessary to indicate the name of the specific PRR agonist used on top of each graph because it is indicated under each graph.</p><p>Figure 5, panel c and Figure 6, panel d: MHC2 should be MHC-II.</p><p>Legend to supplementary figure 2: invert cortical bone surface/bone volume and cortical thickness, in accordance with the order of the graphs in the figure; the last line: CONDITIONNED should be CONDITIONED.</p></disp-quote><p>All these points have been modified in the text and figures.</p><disp-quote content-type="editor-comment"><p>– Figures:</p><p>In general, we suggest the authors present all the data as scatter plots with bars (where applicable), as already done in a number of panels.</p></disp-quote><p>We followed the reviewer's recommendation and presented the data as requested.</p><disp-quote content-type="editor-comment"><p>Figure 1, panel j, first graph: normalized to…?</p></disp-quote><p>&quot;<italic>Normalized to mode</italic>&quot; is a classical representation of FACS data on histograms. It's a normalization made by the sofware (FlowJo) to harmonize the height of the histograms that could change among the graphs depending on the number of cells that have been acquired in each sample.</p><disp-quote content-type="editor-comment"><p>Figure 2: we think it could be interesting to see a representative plot, to visualize double positive cells.</p></disp-quote><p>Unfortunately, in these experiments the markers were analyzed independently so it's not possible to show double positive cells.</p></body></sub-article></article>